Implantable scaffolds for the treatment of sinusitis

Abstract

Materials, devices, kits, and methods are provided that can be used to treat chronic sinusitis. A scaffold that can be used to treat chronic sinusitis includes a tubular scaffold including a plurality of braided polymer strands including a first biodegradable polymer material and a conformal coating on the tubular scaffold including a cross-linked biodegradable elastomer, and is adapted for delivery to human sinus areas. The first biodegradable polymer material includes poly(lactide-co-glycolide). The scaffold includes between 8 and 64 polymer strands.

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of U.S. Provisional Application No. 62 / 186,030, entitled IMPLANTABLE SCAFFOLDS FOR TREATMENT OF SINUSITIS, filed June 29, 2015, U.S. Provisional Application No. 62 / 289,982, entitled IMPLANTABLE SCAFFOLDS FOR TREATMENT OF SINUSITIS, filed February 2, 2016, and U.S. Provisional Application No. 62 / 332,134, entitled IMPLANTABLE SCAFFOLDS FOR TREATMENT OF SINUSITIS, filed May 5, 2016, each of which is incorporated by reference in its entirety herein.

[0002]

[0002] This disclosure describes, among other things, materials, devices, kits, and methods that can be used to treat chronic rhinosinusitis. [Background technology]

[0003]

[0003] Chronic rhinosinusitis (CRS) is a common condition defined by symptomatic inflammation of the paranasal sinuses lasting longer than 12 weeks. Up to 16% of the population suffers from this condition. Cavities involved in CRS include the maxillary, frontal, ethmoid, middle meatal ostium, ethmoid infundibulum, and sphenoid sinuses, as well as the middle meatal region, or a combination of these. Common symptoms of CRS include impaired nasal obstruction, facial pressure or moon face, nasal discharge, and anosmia, which may result from mucosal inflammation, local infection, and / or mucociliary function.

[0004]

[0004] Although there are no approved therapies for the treatment of CRS, evidence-based medical management supports the use of a host of oral or topical corticosteroid therapies for the disease. High-volume daily saline irrigation, along with adjunctive application of topical corticosteroids via nasal spray, is a common first-line therapy. Second-line options for recurrent and worsening disease include short-term oral corticosteroids, but this approach can result in unintended systemic side effects, including glaucoma, osteoporosis, and avascular necrosis of the hip and shoulder. Up to 12-15% of CRS patients are predicted to not respond favorably to this recommended medical regimen and are often candidates for functional endoscopic sinus surgery (FESS) and / or balloon sinuplasty dilation.

[0005]

[0005] Avoidance of surgical intervention in the treatment of CRS would be ideal for patients, as these procedures have surgery-related risks, cause postoperative pain and discomfort, and require cumbersome and costly postoperative cleanup. Clinical data have demonstrated that topical corticosteroids are effective in reducing inflammation associated with CRS and are therefore a reasonable choice for managing this condition.

[0006]

[0006] An ideal treatment for CRS would involve localized and sustained delivery of anti-inflammatory drugs to the patient's sinus area as an alternative treatment option to sinus surgery. Such a therapy would ideally establish safe, effective, sustained drug delivery localized to inflamed tissue, potentially obviating the need for surgery.

[0007]

[0007] FESS involves the removal of bone and tissue to expand the sinus outflow tract and widen the sinus entrances or ostia, allowing restoration of ventilation and mucociliary clearance within previously obstructed sinus cavities. Currently, approximately 500,000 procedures are performed annually in the United States.

[0008]

[0008] FESS has proven to be an effective method to improve sinus drainage pathways by removing small pieces of bone, polyps, and / or debridement of tissue within the sinus cavity. However, a significant number of postoperative complications are often observed, including inflammation, swelling, disease recurrence, the need for repeated procedures, and adhesions. Thus, postoperative care is an important component of FESS. Approximately 10-20% of FESS patients are refractory and do not respond to treatment and may require additional surgical intervention or lifelong medical therapy.

[0009] Some form of sinus packing is commonly performed after FESS. Examples of packing materials include simple saline-moistened dressings, polysaccharide gel-based foam dressings, PEG-based materials, and middle meatus spacers. Implantable sinus stents have also been considered; these scaffolds are intended to stabilize the sinus entrances and turbinates, reduce edema, and / or prevent obstruction due to tissue adhesions. These stents also have the ability to be integrated with therapeutic agent(s) that can be delivered locally over time. This local delivery of therapeutic agent(s) is believed to be superior to topical application in the postoperative setting. In this regard, the USFDA-approved PROPEL™ system (Intersect ENT, Menlo Park, CA, USA) is a self-expanding, bioabsorbable, steroid-eluting stent intended for use in the ethmoid sinus after FESS. Summary of the Invention [Means for solving the problem]

[0010]

[0010] As used herein, the terms "sinus" and "sinus cavity" refer to both sinus cavities and nasal cavities, including, for example, the maxillary, frontal, and ethmoid sinuses, the ostial meatus complex, the ethmoid infundibulum, and the sphenoid sinus, and the middle nasal meatus (sinus cavity).

[0011]

[0011] The present disclosure describes a variety of sinus scaffolds having fiber-based and non-fiber-based designs. These designs vary in shape, size, and delivery site (i.e., maxillary, frontal, ethmoid, sphenoid, and middle meatus). Additionally, therapeutic agent(s) may be optionally included within the scaffold for localized delivery over short or long periods of time. Thus, these scaffolds may be used to improve sinus patency, for example, in surgically repaired sinus spaces or sinus spaces that have not previously undergone surgical repair. Additionally, these scaffolds may be used to deliver local therapeutic agent(s) to such sinus spaces, for example, as part of a treatment plan that is an alternative to sinus surgery (e.g., FESS) or otherwise, including as part of post-operative care of FESS in some embodiments.

[0012] In various aspects, the present disclosure relates to a generally tubular scaffold configured for implantation within a sinus cavity of a patient. As used herein, "generally tubular" includes hollow shapes of circular or non-circular (e.g., elliptical, etc.) cross section, and hollow shapes of constant or variable diameter (e.g., tapered diameter, as in the case of a hollow frustum). The generally tubular scaffold may be open at both ends, open at one end and closed at the other end, or closed at both ends. Many beneficial embodiments described herein use a generally tubular scaffold in the shape of a hollow cylinder open at both ends (i.e., having a circular cross section and a constant diameter). The scaffold may have a fiber-based or non-fiber-based structure and may include a scaffold material and an optional conformal coating including a coating material at least partially covering the scaffold material.

[0013]

[0013] The scaffold material may or may not contain a therapeutic agent selected, for example, from the therapeutic agents described elsewhere in this specification, among other possibilities.

[0014] When the scaffold includes a therapeutic agent, the scaffold can be provided with a variety of release profiles.

[0014]

[0015] In some embodiments, the scaffolds are capable of demonstrating certain cumulative release characteristics when subjected to an in vitro assay in which the scaffolds are immersed in a PBS buffer solution of pH 7.4 containing 2 wt% SDS at 37°C with gentle shaking on a rotary shaker, the volume of the buffer solution in which the scaffolds are immersed is at least 10 times greater than the volume of the buffer solution in which the amount of therapeutic agent corresponding to the total amount of therapeutic agent in the scaffold is at the saturation point of the buffer solution (sometimes referred to as the sedimentation state), and the buffer is completely removed and replaced with fresh buffer every week for quantification.

[0015]

[0016] After one week under such in vitro conditions, the scaffolds may demonstrate a cumulative release of therapeutic agent based on the total amount of therapeutic agent within the scaffold ranging from 1% or less to 70% or more (e.g., ranging from 1% to 2%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%) (i.e., ranging between any two of the aforementioned values), in certain embodiments, beneficially ranging from 2% to 50%, and more beneficially ranging from 5% to 30%.

[0016]

[0017] Alternatively or additionally, after two weeks under such in vitro conditions, the scaffold may demonstrate a cumulative release of therapeutic agent based on the total amount of therapeutic agent within the scaffold ranging from 5% or less to 80% or more (e.g., ranging from 5% to 7%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%) (i.e., ranging between any two of the aforementioned values), in certain embodiments, beneficially ranging from 7% to 50%, and more beneficially ranging from 10% to 30%.

[0017]

[0018] Alternatively or additionally, after 4 weeks in such in vitro conditions, the scaffold may demonstrate a cumulative release of therapeutic agent based on the total amount of therapeutic agent within the scaffold ranging from 10% or less to 90% or more (e.g., ranging from 10% to 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%) (i.e., ranging between any two of the aforementioned figures), in certain embodiments, beneficially ranging from 20% to 75%, and more beneficially ranging from 30% to 60%.

[0018]

[0019] Alternatively or additionally, after 8 weeks in such in vitro conditions, the scaffold may demonstrate a cumulative release of therapeutic agent based on the total amount of therapeutic agent within the scaffold ranging from 25% or less to 100% (e.g., 20% to 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%) (i.e., ranging between any two of the aforementioned values), in certain embodiments, beneficially ranging from 30% to 90%, and more beneficially ranging from 40% to 80%.

[0019]

[0020] In some embodiments, the scaffolds can demonstrate a certain accumulation in vivo release profile.

[0021] For example, after one week in vivo in a human sinus or rabbit sinus, the scaffold may demonstrate a cumulative release of therapeutic agent based on the total amount of therapeutic agent within the scaffold ranging from 1% or less to 45% or more (e.g., 1% to 1.5%, 2%, 3%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%) (i.e., ranging between any two of the aforementioned values), in certain embodiments, advantageously ranging from 1.5 to 35%, and more advantageously ranging from 3% to 20%.

[0020]

[0022] Alternatively or additionally, after two weeks in vivo in the human sinuses or rabbit sinuses, the scaffolds may demonstrate a cumulative release of therapeutic agent based on the total amount of therapeutic agent within the scaffold ranging from 3% or less to 50% or more (e.g., ranging from 3% to 5%, 7%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%) (i.e., ranging between any two of the aforementioned values), in certain embodiments, beneficially ranging from 5% to 35%, and more beneficially ranging from 7% to 20%.

[0021]

[0023] Alternatively or additionally, after 4 weeks in vivo in the human sinus or rabbit sinus, the scaffold may demonstrate a cumulative release of therapeutic agent based on the total amount of therapeutic agent within the scaffold ranging from 7% or less to 60% or more (e.g., ranging from 7% to 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%) (i.e., ranging between any two of the aforementioned values), in certain embodiments, advantageously ranging from 15% to 50%, and more advantageously ranging from 20% to 30%.

[0022]

[0024] Alternatively or additionally, after 8 weeks in vivo in the human antrum or rabbit antrum, the scaffold may demonstrate a cumulative release of therapeutic agent based on the total amount of therapeutic agent within the scaffold ranging from 15% or less to 100% (e.g., ranging from 15% to 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%) (i.e., ranging between any two of the aforementioned values), in certain embodiments, advantageously ranging from 20% to 60%, and more advantageously ranging from 25% to 55%.

[0023]

[0025] In embodiments in which the scaffold comprises a fiber-based structure, the scaffold may comprise a braided structure containing one or more strands of scaffold material.

[0026] In some embodiments that may be used in conjunction with any of the above aspects and embodiments, the braided structure may include sets of opposing helical strands, for example, each set of helical strands may include between 2 and 64 members, more typically between 8 and 32 members.

[0024]

[0027] In some embodiments that may be used in conjunction with any of the above aspects and embodiments, a braided structure may include a first strand of material having a first stiffness and a second strand of material having a second stiffness greater than the first stiffness. As a particular example, the second strand of material may have a modulus of elasticity >3GPa, which may be at least twice the modulus of elasticity of the first strand of material.

[0025]

[0028] In some embodiments that may be used in conjunction with any of the above aspects and embodiments, the braided structure may include cells of different sizes. For example, among other possibilities, a portion of the braided structure may be removed to form cells of different sizes, or the braided structure may be braided to form cells of different sizes. In some cases, the cells of different sizes may include a first cell having a first area and a second cell having a second area, the first area being at least 50% greater than the second area. The variation in cell size may occur, for example, along the length of the scaffold and / or along the circumference of the scaffold.

[0026]

[0029] In some embodiments that may be used in conjunction with any of the above aspects and embodiments, the scaffold may include longitudinal elastomeric fibers that are mechanically coupled to two or more nodes of the braided structure.

[0027]

[0030] In some embodiments that may be used in conjunction with any of the above aspects and embodiments, one or more ends of one or more strands are woven and bonded to the original braided structure.

[0028]

[0031] In some embodiments, the generally tubular scaffold of the present disclosure is wound into a spiral tubular structure. In some of these embodiments, the elongate members take the form of ribbon-shaped elongate members wound into a spiral tubular structure. The ribbon-shaped elongate members may take the form of, for example, a solid film or may include apertures (e.g., formed by forming holes in a solid film, formed by crisscrossing fibers in a braided structure, etc.).

[0029]

[0032] In some embodiments, the generally tubular scaffold of the present disclosure comprises a scaffold material including a plurality of parallel open hoops. In some of these embodiments, the open hoops are ribbon-shaped open hoops. The ribbon-shaped open hoops may be in the form of, for example, a solid film or may include apertures.

[0030]

[0033] In some embodiments, the generally tubular scaffold of the present disclosure comprises a scaffold material that includes a braided structure. In some of these embodiments, the braided structure may include a single strand that can be pulled to unravel and remove the scaffold.

[0031]

[0034] In some embodiments, a generally tubular scaffold of the present disclosure may include multiple radially expandable inserts within the generally tubular structure, in some of these embodiments, each of the radially expandable inserts may include a hub and multiple radially expandable arms or may include a braided hoop, among other possibilities.

[0032]

[0035] In some embodiments that may be used in conjunction with any of the above aspects and embodiments, a distal end of the generally tubular scaffold may be configured to be captured by an additional device, and the generally tubular scaffold may be configured to be everted and removed by retracting the distal end into a lumen formed by the generally tubular scaffold.

[0033]

[0036] In some embodiments that may be used in conjunction with any of the above aspects and embodiments, the generally tubular scaffold may include a conformal coating formed, for example, from an elastomeric or non-elastomeric coating material. For example, the coating material may be an elastomeric material including poly(L-lactide-co-ε-caprolactone) with urethane crosslinks, urea crosslinks, or both urethane and urea crosslinks; the coating material may be an elastomeric material including diisocyanate-cured (e.g., hexamethylene diisocyanate-cured, etc.) hydroxy-terminated branched poly(L-lactide-co-ε-caprolactone). The coating material may or may not include a therapeutic agent, for example, selected from therapeutic agents described elsewhere herein, among other possibilities. The coating material may cover alternating regions along the length of the generally tubular scaffold, and / or the coating material may cover the ends of the generally tubular scaffold without covering the regions between the ends of the generally tubular scaffold. In the case of a braided structure, the coating material may cover some nodes of the braided structure while leaving other nodes uncovered. The thickness of the coating material at the nodes of the braided structure may range, for example, from 1 to 100 times the thickness of the coating material between the nodes of the braided structure (e.g., from 1 to any of 2 times, 5 times, 10 times, 25 times, 50 times, 75 times, 100 times the thickness of the coating material between the nodes of the braided structure).

[0034]

[0037] In an embodiment that may be used in conjunction with any of the above aspects and embodiments, the scaffold may have a conformal coating that may be further coated with an additional conformal coating that includes an additional coating material and a therapeutic agent selected from, for example, therapeutic agents described elsewhere herein, among other possibilities. The additional conformal coating may range in thickness, for example, between 1 μm and 25 μm (e.g., thickness ranging from 1 to 2 μm, 5 μm, 20 μm, 25 μm), among other possibilities. In an embodiment, the additional coating material may be a biodegradable polymer, such as poly(lactide-co-ε-caprolactone) or a mixture of poly(lactide-co-ε-caprolactone) and an additional polymer, such as a homopolymer or copolymer of lactide, e.g., poly(lactide-co-glycolide). If included, the additional polymer may be present as a weight percentage of the additional conformal coating, for example, in an amount ranging from 5 to 50%. Poly(lactide-co-ε-caprolactone) may have, among other possibilities, a mole percentage of lactide ranging, for example, from 50 to 95%, and a mole percentage of caprolactone ranging, for example, from 50 to 5%. When present, poly(lactide-co-glycolide) may have, among other possibilities, a mole percentage of lactide ranging, for example, from 50 to 99.9%, and a mole percentage of glycolide ranging, for example, from 50 to 0.1%. In certain embodiments, the additional conformal coating may comprise one or more biodegradable polymers at 50 to 99.9 wt% (e.g., 50 to 60 wt%, 70 wt%, 80 wt%, 90 wt%, 95 wt%, 99 wt%c, 99.5 wt%, 99.9 wt%), among other possibilities, and mometasone furoate at 0.1 to 50 wt% (e.g., 0.1 to 0.5 wt%, 1 wt%, 5 wt%, 10 wt%, 20 wt%, 30 wt%, 40 wt%, 50 wt%). A typical amount of mometasone furoate is, for example, 0.1 μg / mm, among other possibilities. 2 Below 20μg / mm 2(i.e., mometasone furoate ranges from 0.1 or less to 20 μg or more per square mm of scaffold surface area, where the scaffold surface area A is calculated as A=nDL, where D is the fabricated diameter of the scaffold and L is the fabricated length of the scaffold), e.g., 0.1 μg / mm 2 to 0.2 μg / mm 2 0.5μg / mm 2 1μg / mm 2 2μg / mm 2 5μg / mm 2 , 10μg / mm 2 , 15μg / mm 2 20μg / mm 2 (i.e., ranging between any two of the preceding values), and more typically 1 μg / mm 2 to 10 μg / mm 2 This ranges from...

[0035]

[0038] In an embodiment that may be used in conjunction with any of the above aspects and embodiments, the scaffold may be further coated with a conformal topcoat layer disposed on the additional conformal coating containing the additional coating material and the therapeutic agent. The topcoat layer may be formed of a single biodegradable polymer or a blend of biodegradable polymers, for example, selected from those described elsewhere herein. In an embodiment, the topcoat layer may be formed of the same polymer or polymers as the underlying additional conformal coating, but will not contain a therapeutic agent. The topcoat layer may be used, for example, to delay and / or slow the release of the therapeutic agent in the underlying additional conformal coating. The topcoat layer may range in thickness, for example, between 1 μm and 30 μm, among other possibilities.

[0036]

[0039] In another aspect, the disclosure relates to a method of treatment comprising: (a) introducing a scaffold, such as a scaffold according to any of the above aspects and embodiments, into a patient's sinus cavity while in a radially constrained configuration; and (b) releasing the constraints maintaining the scaffold in the constrained configuration, allowing the scaffold to self-expand within the sinus cavity. Examples of sinus cavities suitable for device implantation include the ethmoid sinus, middle meatal space, frontal sinus ostium (also called the frontal recess), maxillary sinus ostium, and sphenoid sinus ostium, among others.

[0037]

[0040] In yet another aspect, the present disclosure relates to a kit comprising: (a) a scaffold, such as a scaffold according to any of the above aspects and embodiments; (b) a delivery catheter; and (c) an optional injection aid. In an embodiment, the scaffold according to any of the above aspects and embodiments may be placed in a delivery catheter of 15 French or less, a delivery catheter of 9 French or less, a delivery catheter of 6 French or less, or even a delivery catheter of 4 French or less. In an embodiment, the scaffold according to any of the above aspects and embodiments may be placed in a delivery catheter of 6.5 French to 9 French. The catheter may be placed within the ench catheter.

[0038]

[0041] In some embodiments, the delivery catheter may be configured to maintain the scaffold in a radially constrained shape and to release the constraints maintaining the scaffold in said radially constrained shape at the delivery site.

[0039]

[0042] In some embodiments that may be used in conjunction with any of the above aspects and embodiments, a delivery catheter may include an expandable device, such as a balloon catheter that includes a catheter shaft having an inflation lumen and one or more inflatable balloons disposed at or near the distal end of the catheter shaft, where the one or more inflatable balloons may or may not be at least partially coated with a coating containing a therapeutic agent.

[0040]

[0043] In yet another aspect, the present disclosure relates to a delivery system including: (a) a scaffold, such as a scaffold according to any of the above aspects and embodiments, and (b) a delivery catheter, wherein the scaffold is positioned in a radially constrained configuration within the delivery catheter. Such a delivery system may be used in a method of treatment, for example, including the steps of: (a) introducing the scaffold into a patient's sinus cavity while in the radially constrained configuration such that the scaffold is positioned at a delivery site within the sinus cavity; and (b) releasing the constraints maintaining the scaffold in the radially constrained configuration such that the scaffold self-deploys within the sinus cavity.

[0041]

[0044] In yet another aspect, the present disclosure relates to a delivery system including (a) a scaffold, such as a scaffold according to any of the above aspects and embodiments, and (b) a delivery catheter including an expandable device, where the scaffold is positioned above, in, below, proximal, or distal to the expandable device. For example, the expandable device may be an expandable frame or an inflatable balloon. For example, the delivery catheter may be a balloon catheter including a catheter shaft having an inflation lumen and one or more inflatable balloons disposed at or near the distal end of the catheter shaft, where the one or more inflatable balloons may or may not be at least partially coated with a coating containing a therapeutic agent. Such a delivery system may be used in a method of treatment, for example, including the steps of (a) introducing a scaffold into a patient's sinus cavity such that the scaffold is positioned at a delivery site in the sinus cavity, and (b) expanding the expandable device while the expandable device is positioned within the lumen of the scaffold.

[0042]

[0045] In yet another aspect, the present disclosure relates to a method of forming a coated scaffold comprising: (a) applying a first coating solution comprising a first solvent, a branched biodegradable polymer, and a diisocyanate crosslinker to a scaffold according to any of the above aspects and embodiments; and (b) curing the applied first coating solution at room temperature or at an elevated temperature.

[0043]

[0046] In certain embodiments that may be used in conjunction with any of the above aspects and embodiments, the branched biodegradable polymer may be, for example, a branched poly(lactide-co-ε-caprolactone), such as a branched hydroxy-terminated poly(lactide-co-ε-caprolactone).

[0044]

[0047] In certain embodiments that may be used in conjunction with any of the above aspects and embodiments, the solution may further comprise a chain terminator, for example, the chain terminator may be an alcohol, for example, a C8-C18 alcohol, such as 1-dodecanol and stearyl alcohol, among other possibilities.

[0045]

[0048] In certain embodiments that may be used in conjunction with any of the above aspects and embodiments, the diisocyanate crosslinker may be hexamethylene diisocyanate, among other possibilities.

[0046]

[0049] In certain embodiments that may be used in conjunction with any of the above aspects and embodiments, the first solvent may include dichloromethane or ethyl acetate, among other possibilities. In some of these embodiments, the first solvent may further include anisole as a co-solvent.

[0047]

[0050] In an embodiment that may be used in conjunction with any of the above aspects and embodiments, the scaffold may be a braided structure including one or more strands of scaffold material and a plurality of nodes, and the coating solution may be applied to at least the nodes of the scaffold.

[0048]

[0051] In certain embodiments that may be used in conjunction with any of the above aspects and embodiments, the method may further include applying a second coating solution to the scaffold after applying the first coating solution, the second coating solution including an additional biodegradable polymer (e.g., poly(lactide-co-ε-caprolactone), among other possibilities), a second solvent (e.g., including ethyl formate and anisole, among other possibilities), and a therapeutic agent. The therapeutic agent may be a steroidal anti-inflammatory agent, such as mometasone furoate, among other possibilities.

[0049]

[0052] Another aspect of the present disclosure relates to a coated scaffold formed by a method according to any of the above aspects and embodiments.

[0053] Potential benefits of the present disclosure, particularly in relation to adult and pediatric treatment, include one or more of the following: (a) stabilization of sinus opening / ostium; (b) reduction of adhesions and post-operative adhesions; (c) therapy as an alternative to surgery (e.g., treatment of patients who have failed medical management based on oral and / or topical steroid administration), localized and long-term therapeutic delivery for pre- and / or post-operative care; and (d) therapeutic delivery to refractory patients who do not respond to FESS; (e) prevention of sinus ostium / ostium stenosis following surgical dilatation.

[0050]

[0054] These and other aspects, embodiments, and advantages of the present disclosure will become readily apparent to those of ordinary skill in the art upon review of the following detailed description and claims.

[0055] Additional recited aspects of the present disclosure are set forth in the following paragraphs:

[0056] Aspect 1. A scaffold configured for implantation into a sinus cavity, the scaffold comprising a generally tubular structure having a lumen and comprising a scaffold material and an optional conformal coating comprising a coating material at least partially covering the scaffold material.

[0051]

[0057] Embodiment 2. The scaffold of embodiment 1, wherein the scaffold comprises a fiber-based structure.

[0058] Embodiment 3. The scaffold of embodiment 1, wherein the scaffold comprises a braided structure comprising one or more strands of scaffold material.

[0052]

[0059] Embodiment 4. The scaffold of embodiment 3, wherein the braided structure comprises opposing sets of helical strands.

[0060] Embodiment 5. The scaffolding of embodiment 4, wherein each set of helical strands comprises between 2 and 64 members.

[0053]

[0061] Embodiment 6. The scaffolding of embodiment 3, wherein the braided structure comprises first strands of material having a first stiffness and second strands having a second stiffness greater than the first stiffness.

[0062] Aspect 7. The second strand of material has an elastic modulus of >5 GPa and the first strand of material The scaffold of embodiment 6, wherein the elastic modulus of the strand is at least twice that of the strand.

[0054]

[0063] Embodiment 8. The scaffolding of any of embodiments 3-8, wherein the braided structure comprises cells of different sizes.

[0064] Embodiment 9. The scaffold of embodiment 8, wherein a portion of the braided structure is removed to form cells of different sizes or the braided structure is braided to form cells of different sizes.

[0055]

[0065] Embodiment 10. The scaffold of embodiment 8, comprising a first cell having a first area and a second cell having a second area, the first area being at least 50% greater than the second area.

[0066] Embodiment 11. The scaffold of embodiment 8, wherein the cell size variation occurs along the longitudinal length of the scaffold.

[0056]

[0067] Embodiment 12. The scaffold of embodiment 8, wherein the variation in cell size occurs around the circumference of the scaffold.

[0068] Embodiment 13. The scaffold of any of embodiments 3-12, further comprising longitudinal elastomeric fibers mechanically coupled to two or more nodes of the braided structure.

[0057]

[0069] Embodiment 14. The scaffolding of any of embodiments 3-13, wherein one or more ends of said one or more strands are woven and bonded to the original braided structure.

[0070] Embodiment 15. The scaffold of any of embodiments 3-14, wherein the scaffold comprises said conformal coating comprising a coating material.

[0058]

[0071] Embodiment 16 The scaffold of embodiment 15, wherein the coating material comprises an elastomer.

[0072] Embodiment 17 The scaffold of embodiment 16, wherein the elastomer comprises urethane crosslinks.

[0073] Embodiment 18. The scaffolding of any of embodiments 15-17, wherein the coating material covers some nodes of the braided structure while leaving other nodes uncovered.

[0059]

[0074] Embodiment 19. The scaffolding of any of embodiments 15-18, wherein the coating material covers alternating regions along the length of the braided structure.

[0075] Embodiment 20. The scaffolding of any of embodiments 15-18, wherein the coating material covers the ends of the braided structure but does not cover the areas between the ends of the braided structure.

[0060]

[0076] Embodiment 21. The scaffold of any of embodiments 15-21, wherein the thickness of the coating material at the nodes of the braided structure ranges from 1 to 100 times the thickness of the coating material between the nodes of the braided structure.

[0061]

[0077] Embodiment 22. The scaffold of any of embodiments 15-21, wherein one or more strands of the scaffold material comprise poly(lactide-co-glycolide) and the coating material is an elastomeric material comprising poly(L-lactide-co-caprolactone) with urethane crosslinks, urea crosslinks, or both urethane and urea crosslinks.

[0062]

[0078] Embodiment 23. The scaffold of any of embodiments 15-21, wherein one or more strands of the scaffold material comprise poly(lactide-co-glycolide) and the coating material is an elastomeric material comprising diisocyanate-cured hydroxy-terminated branched poly(L-lactide-co-caprolactone).

[0063]

[0079] Embodiment 24. The scaffold of embodiment 24, wherein the hydroxy-terminated branched poly(L-lactide-co-caprolact) is cured with hexamethylene diisocyanate.

[0080] 25. The scaffold comprises 50 to 99.9 wt % poly(L-lactide-co-caprylamide). 25. The scaffold of any of embodiments 15-21, 23, and 24, further coated with an additional coating material comprising 0.1 to 50 wt % mometasone furoate and 0.1 to 50 wt % tetrahydrofuran (TFA) (D-lactone).

[0064]

[0081] Embodiment 26. The scaffold of embodiment 22, wherein the scaffold is further coated with an additional coating material comprising 50 to 99.9 wt% poly(L-lactide-co-caprolactone) and 0.1 to 50 wt% mometasone furoate.

[0065]

[0082] Embodiment 27. The scaffold of embodiment 3, wherein the braided structure is in the form of a ribbon-shaped elongated member wound into a spiral tubular structure.

[0083] Embodiment 28. The scaffold of embodiment 1, wherein the scaffold comprises an elongated member wound into a spiral tubular structure.

[0066]

[0084] Embodiment 29. The scaffold of embodiment 1, wherein the scaffold comprises a plurality of parallel open hoops.

[0085] Embodiment 30. The scaffold of embodiment 29, wherein the open hoop is a ribbon-shaped open hoop.

[0086] Embodiment 31. The foot of embodiment 30, wherein the ribbon-shaped open hoop has a plurality of apertures. Place.

[0067]

[0087] Embodiment 32 The scaffold of embodiment 31, wherein the multiple apertures create a braided-like structure.

[0088] Embodiment 33. The scaffold of embodiment 1, wherein the generally tubular structure is a braided structure.

[0089] Embodiment 34. The scaffold of embodiment 33, wherein the braided structure comprises a single strand that can be pulled to unravel and remove the scaffold.

[0068]

[0090] Embodiment 35. The scaffold of embodiment 1, comprising a plurality of radially expandable inserts within the generally tubular structure.

[0091] Embodiment 36. The scaffold of embodiment 35, wherein the radially expandable insert comprises a hub and arms expandable in a plurality of radii, or the radially expandable insert comprises a braided hoop.

[0069]

[0092] Embodiment 37. The scaffold of embodiment 1, wherein a distal end of the scaffold is configured to be captured by an additional device, and the scaffold is configured to be inverted and removed from the sinus cavity by pulling the distal end into the lumen.

[0070]

[0093] Example 38. A method of treatment comprising the steps of: (a) introducing a scaffold according to any of Examples 1-37 into a patient's sinus cavity while in a radially constrained configuration; and (b) releasing the constraints maintaining the scaffold in the constrained configuration, such that the scaffold is allowed to self-expand within the sinus cavity.

[0071]

[0094] Aspect 39. The method of aspect 38, wherein the sinus cavity is the ethmoid sinus, the middle meatal space, the frontal sinus ostium, the maxillary sinus ostium, the sphenoid sinus ostium, or the frontal sinus recess.

[0095] Embodiment 40. A kit comprising: (a) a scaffold according to any of embodiments 1-37; (b) a delivery catheter; and (c) an optional injection aid.

[0072]

[0096] Embodiment 41. The kit of embodiment 40, wherein the delivery catheter is configured to maintain the scaffold in a radially constrained shape, and to release the constraints that maintain the scaffold in said radially constrained shape at the delivery site.

[0073]

[0097] Embodiment 42. The kit of embodiment 40, wherein the delivery catheter comprises an expandable device.

[0098] Embodiment 43. The kit of embodiment 40, wherein the delivery catheter is a balloon catheter comprising a catheter shaft having an inflation lumen and one or more inflatable balloons disposed at or near a distal end of the catheter shaft.

[0074]

[0099] Embodiment 44. The kit of embodiment 43, wherein the one or more inflatable balloons are at least partially coated with a coating containing a therapeutic agent.

[0100] Embodiment 45. (a) a scaffold according to any one of embodiments 1 to 37; and (b) a delivery catheter. and a delivery catheter, wherein the scaffolding is positioned within the delivery catheter in a radially constrained configuration.

[0075]

[0101] (a) The scaffold is placed into a sinus cavity of a patient while in a radially constrained configuration. A method of treatment using the delivery system of embodiment 45, comprising: (a) introducing the scaffold into the sinus cavity such that the scaffold is positioned at a delivery site within the sinus cavity; and (b) releasing the constraints maintaining the scaffold in a radially constrained shape such that the scaffold is allowed to self-expand within the sinus cavity.

[0076]

[0102] Embodiment 47. (a) a scaffold according to any one of embodiments 1 to 37; and (b) an expandable disk. and a delivery catheter including a vice, wherein the scaffold is positioned above, in, below, proximal or distal to the expandable device.

[0077]

[0103] 48. The expandable device is an inflatable balloon or an expandable frame. 48. The delivery system of embodiment 47, wherein the delivery system is

[0104] 49. A delivery catheter comprising a catheter shaft having an inflation lumen and a catheter 48. The delivery system of embodiment 47, which is a balloon catheter, comprising: one or more inflatable balloons disposed at or near the distal end of the catheter shaft.

[0078]

[0105] At least one of the one or more inflatable balloons is provided with a therapeutic agent. 50. The delivery system of embodiment 49, at least partially coated with a coating comprising

[0106] In an embodiment 51, (a) a scaffold is introduced into a sinus cavity of a patient, the scaffold being delivered to a delivery site within the sinus cavity. 48. A method of treatment using the delivery system of embodiment 47, comprising: (a) positioning the expandable device within the lumen of the scaffold; and (b) expanding the expandable device while the expandable device is positioned within the lumen of the scaffold.

[0079]

[0107] Embodiment 52. The method of embodiment 51, wherein the expandable device is a balloon.

[0108] Embodiment 53. (a) A first solvent, a branched biodegradable polymer, and a diisocyanate. and (b) curing the applied first coating solution at an elevated temperature to form a coated scaffold, wherein the scaffold is configured for implantation within a sinus cavity, the scaffold having a generally tubular structure having a lumen and comprising a scaffold material.

[0080]

[0109] 54. The branched biodegradable polymer is a branched hydroxy-terminated poly(lactide). -co-caprolactone).

[0110] Embodiment 55. The method of embodiment 53, wherein the scaffold material comprises poly(lactide-co-glycolide). ~One of 54 methods.

[0081]

[0111] Embodiment 56. Any of embodiments 53-54, wherein the first solution further comprises a chain terminator. Some way.

[0112] 57. The diisocyanate crosslinker is hexamethylene diisocyanate. 57. The method of embodiment 56, wherein the chain terminator is 1-dodecanol, or a combination of both.

[0082]

[0113] Embodiment 58. The method of any one of embodiments 53 to 57, wherein the first solvent comprises dichloromethane. method.

[0114] Embodiment 59 The method of embodiment 58, wherein the first solvent further comprises anisole.

[0083]

[0115] 60. A scaffold comprising one or more strands of scaffold material and a plurality of nodes. 60. The method of embodiment 59, wherein the coating solution is applied to at least the nodes of the scaffold.

[0084]

[0116] 61. A second composition comprising a second solvent, an additional biodegradable polymer, and a therapeutic agent. 58. The method of any of embodiments 53-57, further comprising the step of applying a coating solution to the cured scaffold.

[0085]

[0117] Embodiment 62 The method of embodiment 61, wherein the additional biodegradable polymer is poly(lactide-co-caprolactone).

[0118] Aspect 63. Any of aspects 61 to 62, wherein the therapeutic agent is a steroidal anti-inflammatory agent. Some way.

[0086]

[0119] Aspect 64: Any of aspects 61 to 62, wherein the therapeutic agent is mometasone furoate. Law.

[0120] 65. The method of claim 64, wherein the second solvent comprises ethyl formate and anisole. Law.

[0087]

[0121] 66. The first coating solution and the second coating solution are sprayed onto the substrate. The method of any one of embodiments 61 to 65, wherein the compound is attached in a process.

[0122] Embodiment 67. A scaffold formed by the method of any of embodiments 53-66.

[0088]

[0123] Embodiment 68. The scaffold of any of embodiments 1-37, wherein the scaffold material comprises a therapeutic agent.

[0124] Embodiment 69. The scaffold of embodiment 68, wherein the therapeutic agent is a steroidal anti-inflammatory agent.

[0125] Embodiment 70. The foot of any one of embodiments 15 to 26, wherein the coating material comprises a therapeutic agent. Place.

[0089]

[0126] Embodiment 71. The scaffold of embodiment 70, wherein the therapeutic agent is a steroidal anti-inflammatory agent.

[0127] 72. Additional conformal coatings containing additional coating materials and therapeutic agents 27. The scaffold of any of embodiments 15-26, further comprising a coating.

[0090]

[0128] Embodiment 73. The scaffold of embodiment 72, wherein the therapeutic agent is a steroidal anti-inflammatory agent.

[0129] Additional aspects and embodiments of the present disclosure are discussed in the detailed description set forth below. do.

[0091]

[0130] Non-limiting examples of the present disclosure are schematic and not necessarily drawn to scale. The following description, by way of example only, refers to the accompanying drawings, in which each identical or nearly identical component shown is typically represented by a single numeral. For purposes of clarity, not every component is individually numbered, nor are every component of each disclosed embodiment shown, unless illustration is necessary for one of ordinary skill in the art to understand the disclosure. [Brief description of the drawings]

[0092] [Figure 1]

[0131] FIG. 1A is a schematic diagram illustrating various fiber cross sections according to embodiments of the present disclosure.

[0132] FIG. 1B is a schematic diagram of a cross-section of a multi-fiber filament according to two embodiments of the present disclosure. [Diagram 2]

[0133] FIG. 1 is a schematic side view of a self-expanding scaffold according to an embodiment of the present disclosure. [Diagram 3]

[0134] FIG. 3A is a schematic side view of a self-expanding scaffold with a uniform braiding angle according to an embodiment of the present disclosure.

[0135] FIG. 3B is a schematic side view of a self-expanding scaffold with variable braiding angles according to an embodiment of the present disclosure. [Figure 4]

[0136] FIG. 1 is a schematic side view of a self-expanding scaffold having an elastomeric coating according to an embodiment of the present disclosure. [Diagram 5]

[0137] FIG. 1 is a schematic side view of a self-expanding scaffold having elastic cross fibers, according to an embodiment of the present disclosure. [Figure 6]

[0138] FIG. 6A is a schematic side view of a self-expanding scaffold having filaments of different stiffness, according to an embodiment of the present disclosure.

[0139] FIG. 6B is a schematic side view of a self-expanding scaffold with filament segments removed, according to an embodiment of the present disclosure.

[0140] FIG. 6C is a schematic side view of a self-expanding scaffold having covered ends according to an embodiment of the present disclosure.

[0141] FIG. 6D is a schematic side view of a self-expanding scaffold having alternating coated and uncoated sections according to an embodiment of the present disclosure. [Figure 7]

[0142] 1 is a photograph of a self-expanding scaffold with non-uniform cell sizes according to an embodiment of the present disclosure. [Figure 8]

[0143] FIG. 1 is a schematic side view of a self-expanding scaffold having folded ends, according to an embodiment of the present disclosure. [Figure 9]

[0144] FIG. 1 is a diagram of a woven scaffold according to an embodiment of the present disclosure. [Figure 10]

[0145] FIG. 1 is a schematic perspective view of a spiral-shaped self-expanding scaffold according to an embodiment of the present disclosure. [Figure 11]

[0146] FIG. 11A is a photograph of a spiral-shaped self-expanding scaffold formed from a braided tubular scaffold according to an embodiment of the present disclosure.

[0147] FIG. 11B is a photograph of a spiral-shaped self-expanding scaffold formed from two braids according to an embodiment of the present disclosure. [Figure 12]

[0148] FIG. 12A is a schematic perspective view of a self-expanding scaffold having solid strut hoops according to an embodiment of the present disclosure.

[0149] FIG. 12B is a schematic perspective view of a self-expanding scaffold having strut hoops in the form of a two-braid design, according to an embodiment of the present disclosure. [Figure 13]

[0150] 1 is a schematic side view of a conformal tube according to an embodiment of the present disclosure. [Figure 14]

[0151] FIG. 14A is a schematic perspective view of a conformal tube with associated three-dimensional support structures in an expanded form, according to an embodiment of the present disclosure.

[0152] FIG. 14B is a schematic end view of a conformal tube with associated three-dimensional support structures in a crimped form, according to an embodiment of the present disclosure. [Figure 15]

[0153] FIG. 1 is a schematic side view of a scaffold in the form of a one-dimensional polymeric structure, according to an embodiment of the present disclosure. [Figure 16]

[0154] Photographs of an 8 mm diameter scaffold, a 10 mm diameter scaffold, a 20 mm diameter scaffold, and a 31 mm diameter scaffold each with 16 strands according to embodiments of the present disclosure. [Figure 17A]

[0155] FIG. 1 is a graph showing the cumulative absolute mass of mometasone furoate (MF) released in the presence of poly(lactic acid-co-caprolactone) (PLCL) as a drug carrier polymer as a function of time for three different drug loadings, according to embodiments of the present disclosure. [Figure 17B]

[0156] FIG. 17B is a graph showing the cumulative percentage of MF released in the presence of PLCL as a drug carrier polymer as a function of time for the embodiment of FIG. 17A. [Figure 18]

[0157] 1 is a graph showing the cumulative percent mass of MF released in the presence of PLCL as a drug carrier polymer, with and without a topcoat comprising PLCL and PLA, as a function of time for one MF scaffold of 400 μg without a topcoat and three MF scaffolds of 400 μg with different topcoat thicknesses according to embodiments of the present disclosure. [Figure 19]

[0158] 1 is a graph showing the cumulative percentage of MF released in the presence of D,L-PLGA as a drug carrier polymer as a function of time for 400 μg of MF containing three different types of D,L-PLGA, according to embodiments of the present disclosure. [Figure 20]

[0159] FIG. 20A is a photograph of a 31.75 mm scaffold with 16 strands according to an embodiment of the present disclosure.

[0160] FIG. 20B is a photograph of a coated node of a scaffold as in FIG. 20A. [Figure 21]

[0161] 1 is a graph illustrating compressive load versus compressive strain for scaffolds according to embodiments of the present disclosure. [Figure 22]

[0162] Figure 22A is a photograph showing various scaffold designs according to various embodiments of the present disclosure; Figure 22B is a photograph showing various scaffold designs according to various embodiments of the present disclosure; Figure 22C is a photograph showing various scaffold designs according to various embodiments of the present disclosure; Figure 22D is a photograph showing various scaffold designs according to various embodiments of the present disclosure; Figure 22E is a photograph showing various scaffold designs according to various embodiments of the present disclosure. [Diagram 23]

[0163] Figure 23A is a photograph showing the deployment of a scaffold according to an embodiment of the present disclosure in a pig nasal cavity. Figure 23B is a photograph showing the deployment of a scaffold according to an embodiment of the present disclosure in a pig nasal cavity. Figure 23C is a photograph showing the deployment of a scaffold according to an embodiment of the present disclosure in a pig nasal cavity. Figure 23D is a photograph showing the deployment of a scaffold according to an embodiment of the present disclosure in a pig nasal cavity. [Figure 24]

[0164] 1 is a photograph showing a scaffold according to an embodiment of the present disclosure after deployment in a pig nasal cavity. [Diagram 25]

[0165] Photograph showing a 32 filament scaffold having a diameter of 13 mm and a length of 10 mm according to an embodiment of the invention after deployment in the middle nasal meatus in a human cadaver in native condition. [Figure 26]

[0166] 1 is a photograph showing a 16 filament, 10 mm scaffold according to an embodiment of the present disclosure after deployment in the frontal sinus ostium of a human cadaver. [Figure 27]

[0167] Photograph showing a 32 filament scaffold having a diameter of 17.5 mm and a length of 10 mm according to an embodiment of the present disclosure after deployment in the ethmoid sinus of a human cadaver after FESS. [Figure 28]

[0168] Figure 28A is an optical microscope image of a coated 8 mm scaffold with 16 strands, i.e., PLGA (10:90) scaffold, without anisole as a co-solvent during spray coating. Figure 28B is an optical microscope image of a coated 8 mm scaffold with 16 strands, i.e., PLGA (10:90) scaffold, with anisole as a co-solvent during spray coating. Figure 28C is an optical microscope image of a coated 8 mm scaffold with 16 strands, i.e., PLGA (75:25) scaffold, without anisole as a co-solvent during spray coating. Figure 28D is an optical microscope image of a coated 8 mm scaffold with 16 strands, i.e., PLGA (75:25) scaffold, with anisole as a co-solvent during spray coating. [Figure 29]

[0169] Figure 29A shows an optical image of a scaffold coated without anisole as a co-solvent during spray coating, i.e., a scaffold coated with 62 wt% elastomer by weight of the base braid from a solution without anisole as a co-solvent. Figure 29B shows an optical image of a scaffold coated with anisole as a co-solvent during spray coating, i.e., a scaffold coated with 63 wt% elastomer from a solution containing anisole as a co-solvent. Figure 29C shows an optical image of a scaffold coated with anisole as a co-solvent during spray coating, i.e., a scaffold coated with 100 wt% elastomer from a solution containing anisole as a co-solvent. [Figure 30A]

[0170] FIG. 13 is a graph showing the cumulative absolute mass of MF released from three sets of MF-coated scaffolds as a function of time. [Figure 30B]

[0171] FIG. 13 is a graph showing the cumulative percent mass of MF released from three sets of MF-coated scaffolds as a function of time. [Diagram 31]

[0172] FIG. 13 shows the in vivo drug release profile of MF-coated PLGA (10:90) scaffolds and MF-coated PLGA (75:25) scaffolds. [Diagram 32]

[0173] 1 is a graph showing MF concentration in the sinus mucosa of sacrificed rabbits as a function of time after implantation. [Diagram 33]

[0174] Graph showing total MF in vivo (MF on scaffolds combined with MF in the sinus mucosa of sacrificed rabbits) as a function of time. [Diagram 34]

[0175] FIG. 13 is a graph showing the cumulative percent mass of MF released from two sets of MF-coated scaffolds as a function of time. [Diagram 35]

[0176] FIG. 13 is a graph showing the cumulative percent mass of MF released from four sets of MF-coated scaffolds as a function of time. [Figure 36A]

[0177] FIG. 36A is a graph showing the immediate recovery from a first amount of compression of two sets of MF-coated scaffolds with 90 and 128 braid angles as a function of compression time. [Figure 36B]

[0178] FIG. 36B is a graph showing the immediate recovery rate from a second amount of compression of two sets of scaffolds coated with MFs having 90 and 128 braid angles as a function of compression time. [Figure 37A]

[0179] FIG. 37A is a graph showing the recovery 6 hours after a first amount of compression of two sets of scaffolds coated with MF with 90 and 128 braid angles as a function of compression time. [Figure 37B]

[0180] FIG. 37B is a graph showing the recovery 6 hours after the second amount of compression of two sets of scaffolds coated with MF with 90 and 128 braid angles as a function of compression time. [Figure 38]

[0181] FIG. 1 is a schematic diagram of a testing apparatus for performing compression testing according to an embodiment of the present disclosure. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0093]

[0182] The implantable medical device of the present disclosure is a generally tubular device. The scaffold is a self-expanding device in various embodiments. As used herein, "device", "scaffold", "stent", "carrier", and "implant" may be used interchangeably. Similarly, as used herein, "self-expanding" is intended to include a device that is crimped into a reduced delivery configuration for delivery into the body and then tends to expand to a larger appropriate configuration upon release from the delivery configuration without the aid of any additional expansion device or with the partial assistance of balloon-assisted or similarly assisted expansion. As used herein, "strength" and "stiffness" may be used interchangeably to mean the resistance of the medical scaffold of the present disclosure to deformation due to radial force or force exerted by the scaffold against a stationary abutment. Examples of strength and stiffness measurements used to characterize the medical scaffold of the present disclosure include radial resistance and sustained outward force as further described herein.

[0094]

[0183] Scaffolds according to the present disclosure are typically available in a variety of sizes, including a variety of diameters and lengths. It is a tubular device that may be of any size and may be used in various sinus applications. For objects of non-circular cross section, "diameter" refers to width. In some useful embodiments, the diameter of the scaffold as manufactured (or unconstrained) may range from 5 mm or less to 60 mm or more, for example, 5 mm to 10 mm, 15 mm, 20 mm, 25 mm, 30 mm, 35 mm, 40 mm, or 50 mm, 60 mm (i.e., between any two of the aforementioned numbers), typically 5 to 13 mm, or 15 to 30 mm. In some useful embodiments, the length as manufactured (or unconstrained) may range from 5 mm or less to 30 mm or more, for example, 5 mm to 10 mm, 15 mm, 20 mm, 25 mm, or 30 mm (i.e., between any two of the aforementioned numbers), typically 10 mm to 20 mm.

[0095]

[0184] In one advantageous embodiment, the mass of the scaffold ranges from 1 to 20 mg / mm (length). That's fine.

[0185] Unless otherwise indicated, scaffold diameters and scaffold lengths given herein are: Refers to the unconstrained (manufactured) diameter and length.

[0096]

[0186] Many scaffold embodiments of the present disclosure are self-expanding, that is, manufactured at a first diameter. The scaffold may be designed to expand or contract to a second, reduced diameter, subsequently contracted or "crimped" to a second, reduced diameter for placement within a delivery catheter, and then self-expand to the first diameter when pushed out of the delivery catheter at the implantation site. The first diameter may be at least 10% larger than the diameter of the body lumen into which the scaffold is to be implanted in some embodiments. The scaffold may be designed to recover at least about 70%, at least about 80%, at least about 90%, and up to about 100% of its manufactured first diameter in some embodiments.

[0097]

[0187] The scaffold according to the present disclosure includes a method for making the scaffold effective for its intended purpose within the sinus cavity. The scaffold is provided with appropriate expansion and mechanical properties to accommodate the crimping force. Two measures of such mechanical properties as used herein are "radial resistance force" ("RRF") and "continuous outward force" ("COF"). RRF is the force the scaffold exerts in response to a crimping force, and COF is the force the scaffold exerts against a stationary abutment surface. In certain embodiments, the scaffold is configured to have a relatively high RRF to be able to hold open body lumens, cavities, nasal features, and the like, and further configured to have a relatively low COF to avoid exerting potentially harmful forces against the walls of body lumens, optic nerves, brain, and the like. For example, a scaffold of the present disclosure preferably expands to 70-100% of its as-manufactured configuration after being crimped, has an RRF ranging from 50-300 mmHg, and / or has a steep COF ranging from 10-100 mmHg (when delivered into a sinus cavity).

[0098]

[0188] Scaffolds according to the present disclosure may be formed from a variety of polymeric and non-polymeric materials. The scaffold according to the present disclosure may be biodegradable, non-biodegradable, or a combination of both biodegradable and non-biodegradable materials. If biodegradable, the scaffold may be fully absorbed within a short period of time, for example, 3 weeks or less, to a long period of time, for example, 52 weeks or more, after placement in the sinus cavity of the patient. In some embodiments, the generally tubular structure may be fully absorbed at some point after 12 weeks of placement and before 32 weeks of placement. In other embodiments, the biodegradable device may be eliminated through nasal irrigation as opposed to absorption into the nasal mucosa. The device may be designed such that the individual portion(s) are resorbed and broken down into predetermined pieces (typically <10 mm or more, typically <5 mm in the longest dimension) that can be eliminated from the sinuses and nasal cavities through normal mucociliary action and swallowed or nasal discharge. In this way, the amount of acidic resorption by-products (e.g., lactic acid, glycolic acid) contacting the sinus or nasal surfaces may be reduced. This may reduce irritation or inflammation of these and surrounding tissues. Additives that are basic in nature may be added to the device in some embodiments to neutralize acidic by-products and reduce the inflammatory response associated with such by-products. Additionally, multiple materials that bioabsorb at different rates may be combined in some embodiments to reduce the amount of material degrading at any one time and therefore the bioresponse.

[0099]

[0189] In various embodiments, the implantable scaffold comprises a generally tubular structure comprising a scaffold material. Scaffolds according to the present disclosure may be fiber-based or non-fiber-based.

[0100]

[0190] In various embodiments, the scaffolding material may be a biodegradable scaffolding material, typically may be a biodegradable scaffolding material comprising one or more biodegradable polymers. Non-limiting examples of biodegradable polymers for forming the biodegradable scaffolding material include biodegradable polyesters, polycarbonates, polyhydroxyalkanoates, polyanhydrides, and polyorthoesters, non-limiting examples of which include homopolymers of lactic acid (PLA), homopolymers of glycolic acid (PGA), homopolymers of trimethylene carbonate (PTMC). , homopolymer of caprolactone (PCL), homopolymer of polypropylene fumarate (PDO), and homopolymer of dioxane (PDO), as well as copolymers comprising two or more of the aforementioned monomers, such as poly(lactic acid-co-glycolic acid) (PLGA), poly(lactic acid-co-caprolactone) (PLCL), and poly(glycolic acid-co-caprolactone) (PGCL). Preferred copolymers include PLGA with a molar percentage of lactic acid ranging from 10 to 90% and a molar percentage of glycolic acid ranging from 90 to 10%, more typically with a molar percentage of lactic acid ranging from 10 to 75% and a molar percentage of glycolic acid ranging from 90 to 25%; for example, PLGA 75:25 (mol / mol) or PLGA(10:90) (mol / mol) may be used in some embodiments. The composition of the PLGA polymer within these ranges may be optimized to meet the mechanical properties and degradation requirements of the particular application in which the scaffold is to be used. In certain embodiments, the biodegradable scaffolding material may include a prodrug-based polymer, such as polyaspirin, that can be used as a single or secondary component of a generally tubular structure to create a scaffold with controlled degradation therapeutic drug release capabilities.

[0101]

[0191] In various embodiments, the scaffolding material is a non-biodegradable scaffolding material, typically one or more may be a non-biodegradable scaffold material comprising a plurality of non-biodegradable polymers. Non-limiting examples of non-biodegradable polymers for forming the non-biodegradable scaffold material include polyolefins such as polyethylene (HDPE and LDPE) and polypropylene, halogenated polyolefins such as polyvinyl chloride (PVC) and fluoropolymers including polytetrafluoroethylene (PTFE) and perfluoroalkoxyalkanes (PFA), polyaromatics such as polystyrene, polyesters such as polyethylene terephthalate (PET), polyamides such as nylon, silicones, mucoadhesive materials, and biostable polyurethanes (PU).

[0102]

[0192] Scaffolds according to the present disclosure may optionally include a layer of a coating material at least partially covering the scaffold-forming material. The coating may include a coating formed from a coating material.

[0193] Coatings can be used to enhance mechanical properties, control degradation, and regulate the release and regulation of therapeutic agents. Coatings may be applied for a variety of purposes, including control. The coating may cover all or a portion of the scaffold, or in fiber-based techniques, may cover all or a portion of the filaments or strands that form the scaffold. As used herein, "strand" and "filament" may be used interchangeably and include single-filament strands and filaments (also referred to as monofilaments) and multifilament strands and filaments.

[0103]

[0194] When the scaffold to be coated is a fiber-based structure, the coating may be applied to, for example, The coating may be applied to individual strands prior to forming the scaffold or may be applied to the scaffold after the scaffold is formed. If the scaffold is a non-fiber-based structure, the coating may be applied to a solid polymer tube or sheet either before or after removing material using a suitable cutting technique, such as, for example, mechanical or thermal cutting. The coating may be created using any suitable method, including spraying, electrospraying, rolling, dipping, chemical vapor deposition, electrospinning, and / or coextrusion, among others. In some embodiments, the coating may include an additional agent, such as a therapeutic agent, as described in more detail below.

[0104]

[0195] In various embodiments, the coating material may be a biodegradable or non-biodegradable composition. The coating material may be a biodegradable coating material or a combination of both, typically a biodegradable coating material comprising one or more biodegradable polymers, or a non-biodegradable coating material comprising one or more non-biodegradable polymers. Non-limiting examples of biodegradable polymers for forming biodegradable coating materials include the biodegradable polymers listed above. Non-limiting examples of non-biodegradable polymers for forming the non-biodegradable coating material include the non-biodegradable polymers listed above.

[0105]

[0196] In various embodiments, a coating is formed that includes an elastomer. Potential benefits of such coatings include enhanced mechanical properties. For example, the coating may be made from an elastomeric polymer that acts to apply forces to the scaffolding due to its elasticity when compressed or stretched, facilitating radial expansion, thus enhancing resilience and / or radial stiffness, among other properties. An additional potential benefit of the elastomer is that it encapsulates the scaffolding material (which may be of braided construction, among other things), maintains its integrity, and provides a smooth, soft surface, thereby providing good conformability while minimizing tissue irritation at contact points. In this regard, certain aspects of the designs described herein, including those resulting from composite structures and combinations of bioabsorbable filaments and elastomeric coatings, provide properties not achievable from other bioabsorbable stent designs. Potential benefits include higher radial resistance and / or sustained outward force with lower amount of polymer, lower profile (stent wall thickness), and / or better compliance due to spring-like structure at each fiber crossover, thereby allowing delivery to the target site through smaller delivery systems or guide catheters, and / or providing better apposition and compliance to the target site with smaller as-fabricated stent diameters. Better compliance may result in more efficient drug delivery to tissues, resulting in improved tissue contact. In addition, better compliance may facilitate handling of the implant after deployment by the surgeon toward the desired location. For example, when realigning one side of the implant, the other side of the implant will tend to realign its position unless it is sufficiently contoured and adhered to the tissue.

[0106]

[0197] Coating thickness for elastomeric coatings can vary widely. A typical thickness may range, for example, from 5 to 50 μm, among other thicknesses. If the braided scaffold is coated, the elastomeric coating may range, for example, between 30 and 150% by weight of the braided scaffold substrate.

[0107]

[0198] Elastomers include thermosetting and thermoplastic elastomers. Thermoplastic elastomers advantageously have a glass transition temperature (Tg) below room temperature (25° C.), and more advantageously below 10° C. Thermosetting elastomers can provide high elongation at break with low permanent deformation under cyclic mechanical testing. Examples of elastomers include, for example, poly(glycolide-co-ε-caprolactone) (PGCL) or poly(lactide-co-ε-caprolactone) (PLCL), including poly(L-lactide-co-ε-caprolactone) and poly(D,L-lactide-co-ε-caprolactone). In certain embodiments, PLCL may have a mole percentage of lactide ranging from 20 to 80% and a mole percentage of caprolactone ranging from 80 to 20%, more typically a mole percentage of lactide ranging from 30 to 50% and a mole percentage of caprolactone ranging from 50 to 70%.

[0108]

[0199] In some embodiments, the biodegradable coating material is a diol, triol, tetraol, or The thermosetting elastomers are formed from polymeric polyols, including tetraols, tetraols, and / or higher alcohols. Such polymers may be crosslinked with a crosslinking agent that is a di- or multi-functional small molecule or polymer. For example, crosslinks may be formed by reacting such polymers with di- or multi-functional isocyanates, which may be in the form of small molecules or polymers.

[0109]

[0200] When the coating comprises a thermosetting elastomeric polymer, the crosslink density is preferably The mechanical properties of the crosslinking agent may be varied to obtain a desired crosslinking density. For example, optional chain terminators may be used in thermosetting elastomeric materials such as polyester urethanes to control the crosslinking density. The chemical crosslinking density is adjusted by using chain terminators to control the degree of crosslinking that occurs during polyester-urethane curing. The crosslinking density of the resulting elastomer depends on the concentration of the chain terminator incorporated into the elastomer network. Examples of suitable chain terminators include any suitable monofunctional compound such as monofunctional isocyanates, alcohols, amines, acyl chlorides, and sulfonyl chlorides.

[0110]

[0201] In one embodiment, the thermoset elastomer is a polyester polyol, a diisopropyl ether polyol, Such thermoset elastomers may be prepared by a process comprising: at least partially dissolving a polyester polyol in a solvent to form a solution; adding a diisocyanate crosslinker to the solution; optionally adding a chain terminator to the solution; coating the solution onto a scaffolding material; and curing the solution. If a solvent-based process is used, less volatile co-solvents can be used to improve the accumulation of thermoplastic elastomers at nodes during the coating process.

[0111]

[0202] Non-limiting examples of suitable polyols for forming urethane crosslinked elastomers include: Examples of suitable polyols include branched (three-arm or greater) poly(lactic acid-co-caprolactone) (PLCL) and poly(glycolide-co-caprolactone) (PGCL) polyols. In addition to branched polymers, linear polymeric diols may be used to create elastic coatings by curing with isocyanates (e.g., hexamethylene diisocyanate) and other suitable reagents. To reduce inflammation caused by material degradation, poly(trimethylene carbonate) (PTMC)-based polyols may be used to create elastic coatings. Various catalysts may be used to facilitate the curing process, including, but not limited to, Sn(Oct)2, Zn(Oct)2, dibutyltin dilaurate (DBTL), 1,4-diazabicyclo[2.2.2]octane (DABCO), and 1,8-diazabicycloundec-7-ene (DBU).

[0112]

[0203] In some embodiments, the scaffold and / or coating conforms to the sinus structure. Shape memory polymers may be fabricated that can change size, shape, and / or compliance to be molded in a flexible manner. Non-limiting examples of shape memory polymers include segmented polyurethanes made with oligolactide, oligocaprolactone, oligolactide-co-glycolide, oligo(trimethylene carbonate) or oligodioxanone linked isocyanates and various chain extenders, (multi)block copolymers of lactide(glycolide) and caprolactone, dioxanone or trimethylene carbonate, polymer blends of polylactide and polyamide elastomers.

[0113]

[0204] As previously mentioned, scaffolds according to the present disclosure may be fiber-based or non-fiber-based. In fiber-based embodiments, the polymeric material may first be fabricated into fibers having cross-sectional dimensions ranging, for example, from 10 μm to 1000 μm, more typically from 100 μm to 300 μm. Such fibers may be formed using a number of techniques including, for example, extrusion or spinning techniques.

[0114]

[0205] The cross-sectional shape of the fibers may vary widely. Possible cross sections include fibers having round cross sections 10, elliptical cross sections 12, and polygonal cross sections (e.g., triangular cross sections 14, quadrilateral cross sections 16, such as rectangular, parallelogram, trapezoidal, pentagonal cross sections, and hexagonal cross sections 18). Fiber cross sections can be varied by selecting the appropriate cross section die for use during fiber production.

[0115]

[0206] The polymeric material may be, for example, cast or extruded using a suitable casting or extrusion process (e.g., solvent casting). The sheet may be formed into a sheet through various techniques, such as melt casting, solvent-based extrusion, melt extrusion, etc. The sheet may then be cut into fibers (e.g., fibers having polygonal cross-sections, e.g., triangular or quadrilateral shapes such as rectangles, parallelograms, trapezoids, etc.).

[0116]

[0207] The strength of the fiber can be improved, for example, by drawing at a suitable draw ratio or annealing at a suitable temperature. This can be optimized in some embodiments by filtering.

[0208] The strength and / or flexibility of the fibers can be determined by multifilament construction of fibers of homogeneous or heterogeneous cross-section. The fibers may be optimized by braiding them into a single fiber strand (e.g., a fishnet type structure). The braided fibers may be of the same or different composition. Furthermore, the braided fibers may be of the same or different diameters. Two embodiments are shown in FIG. 1B, which shows (a) a cross section of a multifilament strand 11 formed from strands of the same material and having the same diameter, and (b) a cross section of a multifilament strand 13 formed from strands of different composition and having different diameters.

[0117]

[0209] Once the polymer strands are prepared, they can be used to fabricate fiber-based scaffolds. For example, monofilament and / or multifilament strands of various shapes (e.g., as shown in Figures 1A-1B, among others) may be braided into a generally tubular structure. The strands forming the braid may vary widely in diameter, for example, ranging from 10 to 1000 μm, among other possibilities. In certain embodiments, the material forming the strands may have an elastic modulus in the range of about 1 GPa to about 10 GPa, more preferably in the range of about 4-9 GPa.

[0118]

[0210] To facilitate the low profile aspects of the present disclosure (e.g., small diameter sinuses In certain advantageous embodiments, the strands used to form the scaffold may have a diameter ranging from 100 to 500 μm, more advantageously from 125 to 250 μm. The use of small diameter strands results in a scaffold with minimal wall thickness and the ability to collapse (i.e., crimp) in a low diameter catheter delivery system. In certain embodiments, the diameter of the strands may be selected to allow the scaffold to be delivered through a 15 French or smaller delivery catheter, a 9 French or smaller delivery catheter, a 6 French or smaller delivery catheter, or even a 4 French or smaller delivery catheter.

[0119]

[0211] FIG. 2 illustrates a cross-sectional view of a tubular member having a length 130, a width 131, and first and second ends 132 along the longitudinal dimension. 1 shows an embodiment of a braided scaffold 100 including at least one strand (e.g., a monofilament or multifilament strand) woven to form a substantially tubular configuration having a length of 133 and a length of 233. For example, the tubular structure may include two sets of strands 110 and 120, each set extending in an opposing helical configuration along the longitudinal dimension of the scaffold. In an embodiment, the number of helical strands forming the scaffold may range, for example, from 8 to 48 strands, among other possibilities. The sets of strands 110 and 120 cross each other at a braid angle 140. The braid angle 140 may range, for example, from about 30 degrees or less to about 150 degrees or more, among other values, such as from 30 degrees to any of 40 degrees, 50 degrees, 60 degrees, 70 degrees, 80 degrees, 90 degrees, 100 degrees, 110 degrees, 120 degrees, 130 degrees, 140 degrees, 150 degrees (i.e., between any two of the aforementioned values). The strands may be woven together using a variety of methods known in the art, including, for example, various 1×1, 1×2, and 2×2 designs, and may be woven using specific known weaving patterns, such as the regular pattern "1 wire, 2 over / 2 under", the diamond half load pattern "1 wire, 1 over / 1 under", or the diamond pattern "2 wire, 1 over / 1 under".

[0120]

[0212] Among other things, the diameter(s) of the strands, the braiding angle 140, and the material of the strands. Various factors contribute to the radial strength of scaffold 100, including the number of strands (or strands) and the number of strands used.

[0121]

[0213] The strands may be fixed or aligned along the circumference of the scaffold and / or along the longitudinal dimension of the scaffold. The filaments may cross over one another at a braiding angle that may vary along the length of the scaffold 100. FIG. 3A illustrates an embodiment in which the scaffold 100 has strands with a constant braiding angle, while FIG. 3B illustrates an embodiment in which the scaffold 100 has strands with a variable braiding angle. In the particular embodiment of FIG. 3B, a first region 100a having strands with a first braiding angle transitions to a second region 100b having strands with a second braiding angle that is less than the first braiding angle. A variety of filament braiding patterns may be used to manufacture such constructs.

[0122]

[0214] Potential attributes of designs with variable braid angles include, among others, one or more of the following: These features include: (1) allowing orientation of segments at specific densities for preferential therapeutic delivery; (2) allowing tailored radial forces depending on the scaffold site; and (3) may be used to provide tapered tubular designs useful for non-cylindrical anatomical structures.

[0123]

[0215] Generally, the shape and diameter of a scaffold according to the present disclosure varies along the length of the device. In some embodiments, in a cylindrical design, the diameter of the device at each end may be larger than the diameter at the midpoint (e.g., dumbbell or hourglass shape). For example, the diameter of the device at each end may be 1.5 times or more, or even 2 times or more, the diameter at the midpoint. In another example, the shape of the device may be triangular at one end and hexagonal at the other end.

[0124]

[0216] The radial stiffness of the braided scaffold is determined by the intersection points of the various strands ("nodes"). The nodes may be adjusted by partially or completely fixing the strands (also referred to as "nodes") at the crossover points, for example, using heat (e.g., using a suitable laser such as a pico or femto laser), by welding the strands at the crossover points, by using a suitable adhesive, by wrapping the crossover points with a suitable filament, or by coating the crossover points with a suitable material that holds the filaments together, among other possible techniques. In some embodiments, an elastomer may be coated onto the braid using procedures such as those described in U.S. Pat. Nos. 8,137,396, 8,540,765, and 8,992,601, the disclosures of which are incorporated herein by reference.

[0125]

[0217] The underlying braid may or may not have fixed knots. , and can be subjected to an elastomer coating. One embodiment is shown in Figure 4, which shows a braided scaffold 100 completely coated with elastomer 100e. By varying the nodal accumulation of the coated elastomer, both the radial resistance force (RRF) and the sustained outward force (COF) may be optimized for this sinus cavity.

[0126]

[0218] In an alternative embodiment, an elastic member such as an elastic filament or strand may be used. Alternatively, elastic filaments or strands 111 may be used to provide a scaffold where the nodes of the braided structure are connected. One such embodiment is shown in FIG. 5, which shows a scaffold 100 with elastic strands 111 attached to the braid 110 at various points along its length. In these embodiments, the braid itself provides a framework to support the sinus cavity, while the elastic filaments or strands 111 are provided to enhance scaffold recovery during deployment. The elastic filaments or strands 111 may be woven into the scaffold 100, for example, during the braiding process, or introduced into the scaffold 100 after the scaffold is formed. In the latter case, the braid 110 forming the scaffold 100 may be made from a softer, inelastic material that conforms to the sinus wall and has a desired degradation profile. The number of elastic filaments or strands 111 used in a given scaffold 100 is adjusted to provide the appropriate recovery and radial stiffness.

[0127]

[0219] A conformable scaffold is desirable in various embodiments, as it improves apposition with contacting tissue. This is because they can be used to improve the delivery of therapeutic agents, reduce damage to contacted tissue, and, if a therapeutic agent is being delivered, also increase therapeutic agent delivery efficacy due to increased tissue contact.

[0128]

[0220] Various strategies can be used to increase the compliance of braided scaffolds. For example, in some embodiments, some or all of the nodes of the braid may be partially fixed or not fixed at all, allowing at least some of the filaments to slide over one another at least somewhat freely. In constrained spaces, a freely movable scaffold will tend to better conform to the geometry of the surrounding environment.

[0129]

[0221] Alternatively, or in addition, the scaffold may be made up of filaments of different stiffness (e.g., more The stiffness of a given strand may be determined, for example, by its inherent material properties, by its processing conditions, and by its dimensions. One embodiment of this type of scaffold is shown diagrammatically in FIG. 6A, where a scaffold 100 is shown formed from higher stiffness strands 112 and lower stiffness strands 113. In certain embodiments, the higher stiffness strands 112 may have a modulus of elasticity greater than 3 GPa and a filament diameter greater than 100 μm, while the lower stiffness strands 113 may have a modulus of elasticity less than 3 GPa and a filament diameter less than 200 μm. The lower stiffness filaments may provide weaker points in the scaffold to allow deformation to accommodate the sinus cavity, whereas the higher stiffness filaments may maintain mechanical integrity.

[0130]

[0222] The adaptability is achieved by removing some of the strands from within the braided structure. , may be improved. One embodiment of this type of scaffold is shown generally in FIG. 6B, which shows a scaffold 100 formed with cells of various sizes. In particular, a scaffold containing larger diamond-shaped cells 114 and smaller diamond-shaped cells 115 is shown. In some embodiments, the severed strands may be partially or completely anchored at the crossover points closest to the severed ends of the strands.

[0131]

[0223] In a related embodiment, the knitting may be performed by, for example, selecting an appropriate knitting pattern. During the braiding process, different sized cells are created. One embodiment of a scaffold 100 having larger braided cells 114 and smaller braided cells 115 is shown in FIG.

[0132]

[0224] When cells of different sizes are formed, the larger cells will overlap the smaller cells. It may have an area ranging from 1.1 times to 10 times or more.

[0225] Potential advantages of a scaffold with a combination of larger and smaller cells include: Larger cells may impart flexibility (eg, to facilitate crimping and better conformability), while smaller cells may maintain mechanical integrity.

[0133]

[0226] Another route to creating adaptive scaffolds is through the use of carbon fiber reinforced silicone, polyimide, among others. The first step is to braid the scaffold using rigid rubber materials such as poly(acrylonitrile butadiene), poly(styrene butadiene) rubber, resulting in a completely elastic braid.

[0134]

[0227] In some embodiments, the coating layer is provided over all or a portion of the scaffold structure. The coating layer may be formed to be relatively inelastic, thereby improving the stiffness of the scaffold (e.g., formed using a relatively stiff polymer such as D,L-PLGA). Furthermore, if the implant is formed using a braid that is inherently elastic, and if the coating layer is a degradable layer, degradation of the degradable layer will result in the scaffold strands having increased compliance.

[0135]

[0228] Furthermore, the coating layer was designed in a certain pattern to adjust the compliance of the braided scaffold. As one particular example, FIG. 6C shows an embodiment of scaffold 100 in which covered regions 116 are provided at each end of scaffold 100, while uncovered regions 117 are provided in the center of scaffold 100. Such a design may be used to provide ends with high stiffness, thus allowing the device to better anchor in the sinus cavity. Furthermore, leaving the middle region of scaffold 100 uncovered may enhance the ability of the stent to conform to the shape of the sinus cavity upon implantation. As another particular example, FIG. 6D shows an embodiment of scaffold 100 in which covered regions 116 and uncovered regions 117 are provided in an alternating pattern. The presence of uncovered regions 117 provides an area of ​​high flexibility along the length of the scaffold, which may provide high conformity to irregular surfaces, such as those associated with sinus cavities.

[0136]

[0229] The areas of coated and uncoated material can be obtained using a variety of techniques. For example, in some embodiments, a mask may be used in the spray coating process to create a particular pattern of coated and uncoated areas.

[0137]

[0230] By masking a portion of the tubular braid in the longitudinal direction during spray coating. , creating a U-shaped coated area (when viewed longitudinally). In these scaffolds, the coated area is relatively stiff, while the uncoated area is relatively soft. It is believed that the coated area provides scaffold recovery after deployment in the sinus cavity. Meanwhile, the soft uncoated area can easily deform to conform to the irregular surface of the sinus cavity, providing optimized conformability. In certain embodiments, such scaffolds can help maintain patency in the case of choosing to create an opening between the left and right paranasal sinuses.

[0138]

[0231] In some embodiments, the scaffold is cut longitudinally to conform to the geometry of the sinus cavity after deployment. The circumference of the scaffold may be easily resized to match the shape of the implant, thus providing better compliance and conformance.

[0139]

[0232] Potential tissue irritation or patient discomfort caused by sharp scaffold edges To reduce the sensitivity of the scaffold, the edges of the scaffold may be coated and / or a braided scaffold may be created in which the end filaments 118 are folded back towards the centre of the scaffold. For example, the filament ends may be woven into the original scaffold structure and bonded, for example, at the nodes. Bonding may be performed using the techniques described above for bonding filaments at the nodes (e.g., welding, applying a suitable adhesive, applying an elastomeric coating, etc.). This type of scaffold 100 is shown diagrammatically in FIG. 8, where the end filaments 118 are folded back towards the centre of the original scaffold 100.

[0140]

[0233] When a short scaffold is braided on a large diameter mandrel (i.e., To the extent difficulties are encountered in forming a scaffold with respect to diameter to length ratio, zigzag strands, including mono- and multifilament strands, may be fabricated prior to braiding. The zigzag strands are then wrapped or looped around a mandrel, preferably in a braiding pattern. The ends of the filaments may then be attached, for example using the techniques described above for joining the filaments at the nodes (e.g., by welding, application of a suitable adhesive, application of an elastomeric coating, etc.), to complete the braided structure. The size and shape of the final scaffold may be controlled by the return angle, orientation, and strut length of the zigzag filaments. Such braids may have turned-up ends as described above.

[0141]

[0234] In some embodiments, the ability to be easily removed when removal is desired. It is beneficial to provide a sinus scaffold that has a hook. In the case of a relatively soft braided scaffold, a tool with one or more hooks at the end may be used to capture the distal end of the implanted scaffold. Alternatively, the device may be removed by standard surgical instruments available to the ENT surgeon. The braid may then be inverted by pulling on its end, thus bringing the outer surface into the lumen. In this way, the scaffold may be removed by peeling it off from the sinus wall, reducing further abrasion, irritation, and damage to the sinus tissue.

[0142]

[0235] Other scaffolds are based on non-knitted or hybrid knitted / non-knitted constructions. Use it as a base.

[0236] For example, in various embodiments, the fabric is formed from woven or knitted strands. A woven or braided scaffolding is provided. A scaffold 100 in the form of a braided tube is shown in FIG. 9. Such woven or braided scaffolds can provide stenting functionality while also being highly compliant and malleable (as well as facilitating therapeutic agent delivery in some embodiments). Furthermore, in the case of a braided structure, in some embodiments, one end of the single strand used to form the tube may be pulled to release the stent, allowing for removal of the scaffold.

[0143]

[0237] In various other embodiments, the scaffold has a spiral (e.g., helical) morphology. In some of these embodiments, the spiral morphology may be formed from a single strand (e.g., a mono- or multi-filament strand). An example of such a scaffold 100 is shown generally in FIG.

[0144]

[0238] In others of these embodiments, the spiral configuration is formed from a multi-stranded construction. Examples of multi-stranded constructs include, for example, substantially two-dimensional structures (e.g., ribbon-shaped structures) that can be molded into a spiral form. Two embodiments of this type of spiral-shaped scaffold are shown in Figures 11A and 11B. In the embodiment shown in Figure 11A, the spiral-shaped scaffold 100 is formed from a pre-existing tubular structure, such as a braided tubular structure (e.g., one of those described above) that is later cut into a spiral. In the embodiment shown in Figure 11B, the scaffold 100 is formed by working up a previously formed substantially two-dimensional braided pattern 119 into a spiral structure, for example, by placing the substantially two-dimensional braided pattern on a mandrel and annealing the two-dimensional braided pattern for a time and temperature appropriate to form the two-dimensional braided pattern into a spiral shape. Examples of such braided patterns include multi-braided braided patterns, such as two-strand (shown in Figure 11B), three-strand, four-strand, etc. braided patterns.

[0145]

[0239] The various braided scaffold analogs described herein are comprised of one-unit polymer structures. It should be noted that the unidimensional polymer structure may take the form of a lattice structure. The unidimensional polymer structure may provide a reduced profile when compared to the use of fiber-based techniques, and thus may provide a minimized profile, which is the sum of the widths of the overlapping strands. One embodiment of such a structure is shown in FIG. 15, which shows a scaffold 100, which is characterized by a regular repeating pattern, such as a lattice structure. The scaffold 100 may be unidimensional. If a polymeric structure, the scaffold may be fabricated using a variety of suitable techniques, such as by mechanically or laser cutting a pattern into a solid polymer tube or ribbon.

[0146]

[0240] In various other embodiments, the scaffold may take the form of an open cylinder. As shown in Figures 12A and 12B, the scaffold 100 may be formed from a series of individual hoops 121 axially aligned with one another and connected at one end. In the embodiment shown in Figure 12A, the individual hoops 121 are solid hoops (e.g., in the form of a ribbon). In the embodiment shown in Figure 12B, the individual hoops 121 include cells, and in particular diamond-shaped cells similar to those formed by braiding. Benefits of these designs may include one or more of the following, among others: the hoops are more likely to crimp in size; the scaffold expands to an expanded diameter after delivery; and because each hoop is capable of expanding to a different width, the scaffold may be better able to conform to spaces of various sizes.

[0147]

[0241] In yet other embodiments, the scaffold 100 may be a polymer such as that shown in FIG. The tube may take the form of a ribbon tube. Such a device is beneficial, for example, because it can conform to the sinus wall 200 and optionally release one or more therapeutic agents. The tube may utilize materials such as the scaffolding materials mentioned above, among others, including heat forged PCL or high caprolactone content PLCL, among many other possible materials.

[0148]

[0242] In the design of the relevant device, a tubular conformal tube as shown in FIG. The normal scaffold may be attached to a crimpable three-dimensional support structure that can assist in the expansion of the scaffold and support the sinuses. A particular example of such a device is shown in FIG. 12, which shows a tubular scaffold 110 attached to a crimpable three-dimensional structure 122. The structure 122 is crimpable for minimally invasive delivery. The structure 122 may be provided at both ends of the tubular scaffold 110, or at one or more points along the length of the tubular scaffold 110, if desired. Examples of suitable materials for forming the crimpable three-dimensional structure include degradable or non-degradable elastomeric materials that can be compressed and recover from the deformation. In other embodiments, a braided stent structure, as discussed above, may be used as the crimpable three-dimensional structure.

[0149]

[0243] Therapeutic agents and supplemental agents, such as inert release controlling agents, may be used in a variety of compositions described herein. It may be integrated into the device.

[0244] Examples of therapeutic agents include small molecule agents, biologics, cells, including stem cells, genes, among others. The therapeutic agent is any suitable agent that exerts a desired biological effect, including RNAi. Specific examples of therapeutic agents include, among others: painkillers including simple analgesics such as aspirin and paracetamol, nonsteroidal anti-inflammatory drugs such as ibuprofen, diclofenac, naproxen, celecoxib, ketoprofen, piroxicam, and sulindac, opioids such as codeintramadol, dextropropoxyphen, paracetamol, morpholine, oxycodone, and pethidine hydrochloride; anesthetics such as lidocaine, bupivacaine, and ropivacaine; Statins such as trovastatin, cerivastatin, fluvastatin, lovastatin, mevastatin, pitavastatin, pravastatin, rosuvastatin, and simvastatin; glucocorticoids, mometasone furoate, beclomethasone dipropionate, budesonide, ciclesonide, flunisonide, fluticasone furoate, fluticasone propionate, dexamethasone, cortisone, prednisone, methylprednisolone, triamcinolone acetonide, betamethasone steroidal anti-inflammatory drugs such as serotonin, dexamethasone, prednisolone, corticosterone, estrogen, sulfasalazine, rosiglitazone, mycophenolate, and mesalamine; H1-receptor antagonists such as diphenhydramine, loratadine, fexofenadine, cyproheptadine, promethazine, desloratadine, chlorpheniramine, hydroxyzine, and pyrilamine; cimetidine, famotidine, lafutidine, nizatidine, ranitidine, roxatidine, and antihistamines, including H2-receptor antagonists such as thiotidine and thiocyanate; antibacterial agents such as mupirocin, gentamicin, and tobramycin; antibiotics such as penicillin, cefoxitin, oxacillin, and tobramycin; endostatin, angiostatin, and thymidine kinase inhibitors, and analogs or derivatives thereof; antileukotrienes (e.g., monteleukast, zafirlukast, zileuton, etc.); antifungal agents; and probiotics.

[0150]

[0245] Other examples of therapeutic agents include heparin, heparin derivatives, urokinase, and PPa. antithrombotic agents such as ck (dextrophenylalanine proline arginine chloromethyl ketone), enoxaparin, and hirudin; antiproliferative agents such as angiopeptin, or monoclonal antibodies capable of blocking smooth muscle cell proliferation, acetylsalicylic acid, paclitaxel, sirolimus, tacrolimus, everolimus, zotarolimus, vincristine, sprycel, amlodipine, and doxazosin; immunosuppressants such as sirolimus, tacrolimus, everolimus, zotarolimus, and dexamethasone; paclitaxel, 5- Antineoplastic / antiproliferative / antimitotic agents such as fluorouracil, cisplatin, vinblastine, cladribine, vincristine, epothilone, methotrexate, azathioprine, halofuginone, adriamycin, actinomycin, and mutamycin; D-Phe-Pro-Arg chloromethylketone, RGD peptide-containing compounds, heparin, antithrombin compounds, platelet receptor antagonists, antithrombin antibodies, antiplatelet receptor antibodies, aspirin (aspirin is also classified as an analgesic, antipyretic, and anti-inflammatory drug), dipyridamidine, cyclosporine ... Anticoagulants such as ridamole, hirudin, prostaglandin inhibitors, platelet inhibitors, and antiplatelet agents such as trapidil or liprostin, tick antiplatelet peptide; DNA demethylating agents such as 5-azacytidine, also classified as an RNA or DNA metabolite, which inhibit cell growth and induce apoptosis in some cancer cells; vascular cell promoters such as growth factors, vascular endothelial growth factor (VEGF, all types include VEGF-2), growth factor receptors, transcription activators, and translation promoters; antiproliferative agents, growth factor inhibitors, growth factor inhibitors, growth factor inhibitors, growth factor receptor ... vascular cell growth inhibitors such as factor receptor antagonists, transcriptional repressors, translational repressors, replication inhibitors, inhibitory antibodies, antibodies directed against growth factors, bifunctional molecules consisting of a growth factor and a cytotoxin, and bifunctional molecules consisting of an antibody and a cytotoxin; cholesterol-lowering agents; vasodilators; and agents that interfere with endogenous vasoactive mechanisms; antioxidants such as probucol; angiogenic agents such as acidic and basic fibroblast growth factors, estrogens including estradiol (E2), estriol (E3), and 17-beta estradiol;Drugs for heart failure such as digoxin, beta-blockers, angiotensin-converting enzyme (ACE) inhibitors including captopril and enalopril, statins, and related compounds; macrolides such as sirolimus and everolimus; agents that have a primary mechanism of action of extracellular matrix remodeling and a secondary mechanism of action of inhibiting cell proliferation, such as 5-fluorouracil, doxycycline, carvedilol, curcumin, and tranilast;

[0151]

[0246] Other treatments have been shown to be beneficial in re-establishing a healthy microbiome in the nasal and sinus areas. Possible sources include bacteria or other microflora, as well as drugs or nutrients that may promote a healthy microflora.

[0152]

[0247] Inert release controlling agents may be included to enhance control of therapeutic agent release kinetics. Examples of inert release controlling agents include soluble polymers such as polyethylene glycol (PEG) (also known as polyethylene oxide, PEO), PEG-vinyl alcohol copolymers, polyacrylates, polymethacrylate esters containing cationic and anionic functional groups, polyvinylpyrrolidones, and dextran, as well as small molecule additives such as cyclodextrins, or citrate esters such as acetyl tributyl citrate (ATBC) or acetyl triethyl citrate (ATEC).

[0153]

[0248] In embodiments in which the scaffold delivers one or more therapeutic agents at the implantation site, the therapeutic agent The therapeutic agent(s) may be provided within the device for delivery therefrom in a number of ways.

[0249] For example, a therapeutic agent can be subsequently used to form the generally tubular scaffolds described herein. The therapeutic agent may be embedded directly into a polymer construct (e.g., a filament, sheet, solid tube, etc.) for use in a therapeutic agent-loaded polymeric material. In one embodiment, the therapeutic agent and polymer(s) are dissolved in a suitable solvent to create a homogenous solution or suspension, or the therapeutic agent and polymer(s) are heated to form a polymer melt containing the therapeutic agent. The solution, suspension, or melt is then subjected to a suitable solvent-based or melt-based processing, such as extrusion, wet spinning, dry spinning, melt spinning, electrospinning, or other process, to obtain a therapeutic agent-loaded polymeric construct (e.g., a filament, sheet, tube, etc.) containing the embedded therapeutic agent. In some embodiments, polymeric regions that do not contain a therapeutic agent (e.g., a polymer core) are coextruded with a therapeutic agent-loaded polymeric coating to form a therapeutic agent-loaded polymeric construct.

[0154]

[0250] In some embodiments, the therapeutic agent-loaded polymer construct is then subsequently processed. The polymeric material may be cast into additional forms that are subsequently used to form the generally tubular scaffolds described herein. As a particular example, a solvent cast therapeutic agent-loaded polymer construct in the form of a sheet may be fabricated by controlled deposition of a solution of a therapeutic agent and one or more carrier polymers. After removal of the solvent(s), the therapeutic agent-loaded polymer sheet may be laser cut into a therapeutic agent-loaded polymer construct in the form of a flat filament for braided fabrication.

[0155]

[0251] In some embodiments, spray coating, dip coating, among others, The therapeutic agent may be attached to a preformed construct (e.g., a filament, sheet, or tube, including a preformed device scaffold) in the presence or absence of a carrier material (e.g., a polymeric coating material as described above) using a suitable attachment technique, such as rolling, or vapor deposition. The therapeutic agent release profile may be adjusted, for example, by the thickness of the coating layer, by the addition of inactive ingredients, and by varying the carrier polymer (e.g., by changing the composition and / or molecular weight of the polymer) and / or by varying the ratio of therapeutic agent to polymer, if a polymer is provided as the carrier.

[0156]

[0252] The topcoat of the polymer layer, which does not contain a therapeutic agent, prevents the therapeutic agent from being transferred from the device to the body tissue. The topcoat may be used to regulate the delivery of therapeutic agents. In embodiments relating to non-biodegradable topcoats, the topcoat may act as a diffusion barrier such that the delivery rate of the therapeutic agent(s) is limited by its diffusion rate through the topcoat. In some embodiments relating to biodegradable topcoats, the topcoat may act as a diffusion barrier such that the delivery rate of the therapeutic agent(s) is limited by its diffusion rate through the topcoat. In other embodiments relating to biodegradable topcoats, the therapeutic agent(s) cannot diffuse through the topcoat and therefore their delivery will simply be delayed until the topcoat has completed decomposition.

[0157]

[0253] Electrospinning is used to deliver therapeutic agents onto preformed constructs. In one embodiment, a fiber-based or non-fiber-based scaffold may be covered by an electrospun fiber mesh, such as a core-sheath fiber mesh. During electrospinning, the therapeutic agent may be dissolved or suspended in the core polymer solution. The therapeutic agent release profile may be tailored by adjusting the therapeutic agent loading, therapeutic agent particle size (if a suspension is used), the type of polymer used to form the core and sheath, respectively, and the thickness of the sheath.

[0158]

[0254] In other embodiments, the core-sheath fiber is a polymer solution containing a therapeutic agent. Or they may be fabricated first through coaxial electrospinning of a suspension and a sheath polymer solution. The therapeutic agent-loaded fibers may be further braided into multi-filament strands that will be used to fabricate the device. For example, composite strands in a fishnet shape may be formed and then fabricated into the braided scaffold described above. In these designs, the release of the therapeutic agent may be dominated by the electrospun fibers.

[0159]

[0255] In some embodiments, biologically active agents such as proteins and / or polysaccharides are Active drugs may be incorporated into the electrospun fibers.

[0256] In some embodiments, the devices described herein may be sty. For example, a scaffold as described herein can be deployed in a sinus cavity with the aid of an expandable device, such as an expandable frame (e.g., an expandable wire frame) or a balloon, among other possibilities. In such embodiments, a scaffold according to the present disclosure may be positioned above, in, below, proximal to, or distal to the expandable device, either at the manufacturing site or at the point of delivery by a healthcare professional. The expandable device may be a drug-eluting device (e.g., via a drug-containing coating disposed on the expandable device) or a non-drug-eluting device. Examples of therapeutic agents released by drug-eluting devices are described above.

[0160]

[0257] Thus, in the case of a balloon, the balloon may or may not be coated. A scaffold according to the present disclosure may be positioned at the manufacturing site or at the point of delivery by a health care professional on top, middle, bottom, proximal or distal of a balloon catheter appropriate for sinuplasuty. The catheter may include an inflatable balloon assembly disposed at or near the distal end of a catheter shaft that includes an inflation lumen for the balloon. In a non-inflated state, the balloon assembly does not significantly increase the overall width of the distal end of the catheter. This allows the distal portion of the catheter to be inserted into the patient and guided to a desired treatment site in the patient's sinus. Once the treatment site is reached, the balloon assembly is inflated to position the scaffold against the sinus wall in the vicinity of the treatment site. The balloon assembly may include any number of individual balloons in several configurations depending on the treatment site. Additionally, sinuplasty may be completed prior to delivery of the scaffold, after delivery of the scaffold, simultaneously with delivery of the scaffold, or any combination of perioperative treatment procedures.

[0161]

[0258] In some embodiments, the devices described herein are used as adjunctive therapy. For example, a scaffold as described herein can be deployed in the sinus cavity using a therapeutic agent-eluting delivery device, such as a therapeutic agent-eluting balloon. Alternatively, the scaffold can be deployed in the sinus cavity after the cavity has been treated with a therapeutic agent-releasing spray, such as a hydrogel spray, or with a irrigation solution containing one of the therapeutic agents previously described in this disclosure.

[0162]

[0259] The scaffolds of the present disclosure are radio-invisible and visible using conventional fluoroscopy techniques. The radiopaque additive, if present, may be included in the polymeric material of the scaffold and / or its coating. Examples of suitable radiopaque additives include particles containing iodine, bromine, barium sulfate, platinum, iridium, tantalum, and / or palladium. In another embodiment, radiopaque groups such as iodine are introduced onto the polymer backbone. In yet another embodiment, one or more biostable or biodegradable radiopaque markers, including, for example, platinum, iridium, tantalum, and / or palladium, may be produced in the form of tubes, coils, wires, spheres, or disks, which are then placed at the ends of the scaffold or at other predetermined locations on the scaffold.

[0163]

[0260] To facilitate delivery, the scaffold is loaded into a delivery catheter immediately prior to implantation into the patient. By loading the scaffold in close temporal proximity to the implant, the possibility of the polymer of the scaffold loosening within the delivery catheter during transport, storage, etc. Thus, one aspect of the present disclosure includes a method of delivering a scaffold of the present disclosure, comprising loading the scaffold into a delivery catheter shortly, e.g., within one hour, prior to implantation into a body lumen. However, it should be noted that the scaffold of the present disclosure does not need to be loaded into a delivery catheter immediately prior to implantation.

[0164]

[0261] In some embodiments, among other uses (e.g., among other devices), The present invention may provide a scaffold suitable for implantation into the vacated space created during ethmoid sinus surgery, for example using a 3 mm catheter. Such scaffolds may range, for example, from 10 to 30 mm in diameter, more particularly from 15 to 20 mm in diameter, among other possible values. Such scaffolds may range, for example, from 5 to 20 mm in length, more particularly from 8 to 12 mm in length, among other possible values. In certain beneficial embodiments, the scaffold comprises a braided scaffold material, which may include, for example, from 8 to 64 braided strands, more particularly from 16 to 32 braided strands, among other possible values. In certain beneficial embodiments, the braid angle may vary, for example, from 30 to 150 degrees, more particularly from 60 to 130, among other possible values. In certain beneficial embodiments, the diameter of the strands forming the braid may vary, for example, from 50 to 500 μm, more particularly from 150 to 300 μm, among other possible values. In some beneficial embodiments, the mass of the scaffold may range, for example, from 1 to 20 mg / mm (length), more particularly from 2 to 10 mg / mm, among other possible values. In some beneficial embodiments, the scaffold has a diameter recovery percentage of at least 85% after being compressed to a diameter of 30% of the unconstrained diameter in 10 minutes. When drug is released, in non-refractory patients, the drug may be released over a period of 3 to 6 weeks, among other values, whereas in refractory patients, the drug may be released over a period of 8 to 26 weeks, among other values.

[0165]

[0262] In some embodiments, among other uses (e.g., among other possible devices), The method may provide a scaffold suitable for implantation in the middle meatus space, for example using a 3-4 mm delivery catheter. Such a scaffold may, for example, range in diameter from 5 to 20 mm, more particularly from 10 to 15 mm, among other possible values. Such a scaffold may, for example, range in length from 5 to 20 mm, more particularly from 8 to 12 mm, among other possible values. In certain beneficial embodiments, the scaffold comprises a braided scaffold material, which may include, for example, 8 to 64 braided strands, more particularly from 16 to 32 braided strands, among other possible values. In certain beneficial embodiments, the braid angle may vary, for example, from 30 to 150 degrees, more particularly from 60 to 130 degrees, among other possible values. In certain beneficial embodiments, the diameter of the strands forming the braid may vary, for example, from 100 to 500 μm, more particularly from 150 to 300 μm, among other possible values. In some beneficial embodiments, the mass of the scaffold may range, for example, from 1 to 20 mg / mm (length), more particularly from 2 to 10 mg / mm (length), among other possible values. In some beneficial embodiments, the scaffold has a diameter recovery % of at least 85% after being compressed to a diameter of 30% of the unconstrained diameter in 10 minutes. In some beneficial embodiments, the scaffold has an RRF, measured with an MSI radial force tester at a diameter less than the as-manufactured diameter, among other possible values, ranging from 30 to 500 mmHg. In some beneficial embodiments, the scaffold has a steep COF, measured with an MSI radial force tester at a diameter less than the as-manufactured diameter, among other possible values, ranging from 5 to 100 mmHg. If a drug is released, the drug may be released over a period of 8 to 26 weeks, among other possible values.

[0166]

[0263] In one embodiment, into the sinus ostium (frontal, maxillary, or sphenoid), among other uses. The present invention may provide a scaffold suitable for implantation into the nasal cavity or into the frontal sinus recess (e.g., using a 3-4 mm delivery catheter, among other possible devices). Such a scaffold may be The diameter may range, for example, from 4 to 20 mm, more particularly from 6 to 10 mm, among other possible values. Such scaffolds may range, for example, from 5 to 20 mm, more particularly from 6 to 12 mm, among other possible values. In some useful embodiments, the scaffold comprises a braided scaffold material, which may comprise, for example, from 8 to 64 braided strands, more particularly from 16 to 32 braided strands, among other possible values. In some useful embodiments, the braiding angle may range, for example, from 30 to 150 degrees, more particularly from 60 to 130 degrees, among other possible values. In some useful embodiments, the diameter of the strands forming the braid may range, for example, from 100 to 500 μm, more particularly from 150 to 300 μm, among other possible values. In some useful embodiments, the mass of the scaffold may range, for example, from 1 to 20 mg / mm (length), more particularly from 2 to 10 mg / mm, among other possible values. In some beneficial embodiments, the scaffold has a diameter recovery percentage of at least 85% after being compressed to a diameter of 30% of the unconstrained diameter for 10 minutes. In some beneficial embodiments, the scaffold has an RRF ranging from 30 to 500 mmHg, among other possible values, as measured by an MSI radial force tester at a diameter less than the as-manufactured diameter. In some beneficial embodiments, the scaffold has a steep COF ranging from 5 to 100 mmHg, among other possible values, as measured by an MSI radial force tester at a diameter less than the as-manufactured diameter. If a drug is released, the drug may be released over a period of 6 to 26 weeks, among other values.

[0167]

[0264] In some aspects, the scaffolds described herein comprise, among other components, may be provided in a kit including (a) one or more scaffolds, (b) a delivery catheter, and (c) an optional delivery aid (e.g., a crimping mechanism). EXAMPLES

[0168]

[0265] Uniformly woven scaffolds (see, for example, Figure 3A) are fabricated by spinning fibers onto individual bobbins. The yarn was first produced using PLGA (85:15) copolymer by winding monofilaments. Each bobbin was placed on a braider, threaded through rollers and eyelets, and wound around a mandrel of the desired OD (e.g., 7, 8, or 10 mm). The braiding tension on the machine was set to suit the size of the monofilament. The pixel / inch was set to give the braiding angle with optimal properties, including radial strength. A braiding pattern was selected and the monofilament was braided from the spool onto the mandrel by the braider. Tie wraps were used at the end of each mandrel to hold tension on the filament, which can be useful for thermal annealing and obtaining high modulus properties. The braided polymer was thermally annealed on the mandrel, then cut to the desired length with a blade and removed from the mandrel.

[0169]

[0266] The braided PLGA scaffolds can be subjected to chain termination with the optional use of a catalyst. The braided scaffolds were coated with a support coating made of poly(L-lactide-co-ε-caprolactone) (PLCL) cured with hexamethylene diisocyanate (HDI) in the presence of 1-dodecanol (DD) as a stimulant. In particular, 4-arm hydroxy-terminated PLCL (40:60) (mol / mol), HDI, and DD were dissolved in dichloromethane to make a stock solution for spray coating. The solution was spray coated onto the braided scaffolds. After full curing at elevated temperature, the scaffolds were cut into various lengths for radial force and recovery testing. Figure 16 shows microscopic images of 8 mm, 10 mm, 20 mm, and 31 mm scaffolds, each with 16 strands and braiding angles of approximately 100 to 135 degrees. Some properties of these and similar scaffolds with different as-manufactured diameters, number of strands, and braiding angles are shown in Table 1 (where @[DO-1]mm refers to a measurement 1 mm less than the as-manufactured diameter, i.e., 6 mm for 7 mm scaffolds, 7 mm for 8 mm scaffolds, and 9 mm for 10 mm scaffolds). All scaffolds showed excellent diameter recovery (Rec.%) after simulated use. These scaffolds have various radial stiffnesses (RRF and COF) depending on the design.

[0170] [Table 1] EXAMPLES

[0171]

[0267] The scaffold prepared in Example 1 was treated with PLCL and mometasone furoate ( The scaffolds were then further coated with an additional conformal coating containing a mixture of PLCL and MF. The PLCL in the MF-containing coating contained approximately 70% (mol%) lactic acid, with the remainder being caprolactone (PLCL 70:30). A homogenous solution of MF and PLCL was prepared in dichloromethane (DMC). The DCM solution was then spray coated onto a 7 mm scaffold with 24 strands.

[0172]

[0268] The amount of MF carried by each scaffold was determined by the thickness and loading of the MF-containing coating. By controlling the thickness between <1 μm and 10 μm and the loading rate of MF from about 1 wt% to about 40 wt% relative to the total dry coating weight, we found that the drug loading for 7 mm diameter scaffolds was beneficially about 10 to 2400 μg per 10 mm of scaffold length, and more beneficially 100 to 1600 μg per 10 mm of scaffold length. Figure 17A shows the cumulative released MF expressed in mass units for scaffolds with different drug loading rates (5, 10, and 20 wt% correspond to 100, 200, and 400 μg of MF per 10 mm of scaffold length). Significantly, we found that the drug release percentage profile was slightly affected by the drug loading rate within a certain range (see Figure 17B). EXAMPLES

[0173]

[0269] To obtain a more linear release profile, PLCL (70:30) and P A topcoat containing LA was further coated onto the drug-coated scaffold. A homogenous solution of 0.75 wt% PLCL and 0.25 wt% PLA was prepared in DCM. The DCM solution was then spray-coated onto a 7 mm scaffold with 24 strands in a single coating layer with variable coating passes resulting in different topcoat thicknesses. As shown in Figure 18, MF release can be tuned by varying the thickness of the topcoat. The thicker the topcoat, the slower the drug release. This approach, combined with different drug loading rates, can easily provide different daily dosages with programmable release durations. EXAMPLES

[0174]

[0270] Biodegradable polymers such as D,L-PLGA were also used as drug carriers. Conformal coatings were formed containing a mixture of D,L-PLGA and mometasone furoate (MF) as the active agent. The coatings contained 20 wt% MF. The D,L-PLGA in the mometasone-containing coatings included D,L-PLGA with approximately 50% lactide and 50% ε-caprolactone (50:50) (mol%), D,L-PLGA with approximately 75% lactide and 25% ε-caprolactone (75:25), or D,L-PLGA with approximately 85% lactide and 15% ε-caprolactone (85:15). In each case, a homogenous solution of MF and D,L-PLGA was prepared in anisole / ethyl formate (50:50 v / v). The solution was then spray coated onto a 7 mm scaffold with 24 strands.

[0175]

[0271] As illustrated in FIG. 19, the composition of the present invention includes these polymers as a coating layer. The drug released from the field is significantly slower than that coated with PLCL (70:30). Without wishing to be bound by theory, in the case of D,L-PLGA, drug release is most easily controlled by the degradation of the carrier polymer, with the drug molecules being released at a later stage after the polymer begins to degrade.

[0176]

[0272] In this context, scaffolds with a bilayer of drug coating have been shown to be It can be manufactured to achieve sustained release of MF. For example, a top layer containing PLCL (70:30) and MF can be formed on a bottom layer containing DL-PLGA and MF. Without being bound by theory, it is believed that in the early stage, the released drug can be dominated by the diffusion-controlled release of MF from the top layer, whereas in the later stage, the drug in the bottom layer can be released with the degradation of DL-PLGA. EXAMPLES

[0177]

[0273] 16 monofilament strands (approx. 0.0165 cm (0.0065 in) Scaffolds consisting of 1000μm filament diameter, PLGA 85:15) were braided on a large diameter mandrel (3.175 cm) in a 1×1 braiding pattern at 25 picks per inch. The scaffolds were then annealed at 130° C. for 24 hours, cut to working length, and then placed on a fixture in preparation for spray coating.

[0178]

[0274] The elastomer solution was prepared by dissolving 5 wt% PLCL in DCM (40:60). A crosslinker, hexamethylene diisocyanate (45:1 NCO:OH), and zinc octoate catalyst (0.1 wt%) were added to the final solution. The elastomer solution was spray coated onto the scaffolds and cured in an open vial at 100° C. for 24 hours. A photograph of one stent thus produced is shown in FIG. 20A, and a photograph of a coated section of such a stent is shown in FIG. 20B.

[0179]

[0275] Plate compression tests were performed to evaluate the mechanical performance of the scaffolds after curing. The scaffolds were compressed longitudinally to 50% of their initial diameter. The results are shown in Figure 21, where the compressive load is per unit length of the scaffold. EXAMPLES

[0180]

[0276] Split the multifilament strand into two 0.007" (0.0178 cm) pieces. )PLGA 85:15 monofilament strands were prepared by twisting them together. The multifilament strands were then handwoven into various braided patterns using a fixture. An example of the fixture used to prepare the multifilament scaffolds is shown in FIG. 22. The fixture was also used to prepare the scaffolds using the monofilament strands. After weaving, the ends of the filaments were fixed to the fixture using tape and subsequently annealed at 100° C. overnight to harden the filaments and maintain the filament crossing points. The scaffolds were then spray coated using an elastomer solution containing 5 wt % PLCL 40:60, HDI (45:1 NCO:OH), and zinc catalyst (0.1 wt %) in methylene chloride. All scaffolds were cured in open vials at 100° C. for 24 hours.

[0181]

[0277] Table 2 shows five different braiding patterns after spray coating (Figures 22A-2 The data included data generated from the 2011 MRI data set (shown in Figure 2E). All scaffolds were measured for diameter, weight, braiding angle, acute recovery rate, and post-deployment recovery rate.

[0182] [Table 2]

[0183]

[0278] The recovery test was carried out by crimping the scaffold and then twisting the outer braid until a crimp diameter of 4 to 5 mm was reached. This was accomplished by delivery through a series of tubes ranging from larger to smaller using a raised mesh sheath. Acute and post-deployment recovery rates are reported as a percentage of the initial diameter. EXAMPLES

[0184]

[0279] The in vivo performance of the scaffold according to the present disclosure was tested in cadaveric pigs. The study utilized a scaffold 2 having a diameter of approximately 7 mm and 32 filament braid (see Table 1, entry 1) in accordance with the present disclosure, delivered through a 7.5F catheter.

[0185]

[0280] The device was implanted into the nasal turbinate folds of porcine cadavers. By withdrawing the outer sheath of the device while holding the sheath in place, the device was deployed in a smooth, controlled manner into the porcine nasal cavity. 23A-23C are photographs showing the deployment process. The delivery catheter was approximately 2.8 mm in diameter. The scaffold expanded to fill the space between the nasal septum and the nasal turbinates, as seen in FIG. 24.

[0186]

[0281] These deployments provide: (a) controlled and precise delivery; (b) improved adhesion to the nasal wall; The present disclosure highlights several potential benefits of the scaffolds, including (a) improved apposition / compliance, and (b) reduced device profile. EXAMPLES

[0187]

[0282] A human cadaveric study will evaluate the clinical performance of the disclosed scaffold in the human anatomy. A series of device prototypes and delivery system prototypes were integrated to test multiple scenarios in representative anatomies, both before and after functional endoscopic sinus surgery. Endpoints included endoscopic appearance and clinical feedback.

[0188]

[0283] Several small diameter scaffold prototypes according to the present disclosure are described in Table 1. Meanwhile, two larger diameter scaffold prototypes are described in Table 3.

[0189] [Table 3]

[0190]

[0284] A scaffold formed using the procedure along the lines described in Example 1 was placed into the middle meatus. The feasibility of placing a 32 filament, 13 mm scaffold in the middle meatus and applying mechanical force to medially displace the middle turbinate and deliver drugs to the ethmoid sinus was demonstrated. Five deployments were performed: (a) 16 filament, 8 mm scaffold, (b) 32 filament, 8 mm scaffold, (c) 16 filament, 10 mm scaffold, (d) 32 filament, 10 mm scaffold, and (d) 32 filament, 13 mm scaffold. All devices conformed relatively well to the tissue, displacing the middle turbinate medially (MT) and exerting an outward force on the uncinate process (UP), but the 32 filament, 13 mm scaffold appeared to provide the best fit for the particular space in which it was implanted. Figure 25 is a photograph illustrating the 32 filament, 13 mm scaffold (10 mm long) after deployment in the middle meatus of a human cadaver. The implant conformed well to the tissue with proper laryngeal formation of the middle turbinate.

[0191]

[0285] A device according to the present disclosure was also placed in the frontal recess of a human cadaver. In this study, the frontal recess was inaccessible prior to surgical intervention. The entrance to the frontal sinus was approximately 1 mm in diameter and could not accommodate the delivery device. Functional endoscopic sinus surgery (FESS) was performed to remove the ethmoid cells and enlarge the access to the frontal sinus. Following this procedure, a 32 filament (Table 1, entry 6) and a 16 filament (Table 1, group 8) implant were deployed within the frontal sinus ostium. Both devices adapted well to the tissue, but the 16 filament device appeared to exhibit a higher adaptability to the specific space in which it was implanted. Figure 26 is a photograph showing a 16 filament, 10 mm scaffold after deployment within the frontal sinus ostium.

[0192]

[0286] In the second cadaver, the frontal sinus ostium was accessible prior to surgical intervention. , 16 filament implants (n=1, from Table 1, entry 8, and n=1, from Table 1, entry 9) were deployed in the frontal sinus before and after FESS, respectively. These implants adapted well to the sinus ostium.

[0193]

[0287] 16 filaments, 10mm diameter scaffold; 4 filaments, 38mm scaffold; A 2 filament, 38 mm scaffold and a 32 filament, 17.5 mm scaffold were placed in the ethmoid sinus of a human cadaver after functional endoscopic sinus surgery, with the 10 mm diameter scaffold appearing smaller than the particular space in which it was implanted, the 38 mm scaffold appearing larger than the particular space in which it was implanted, and the 17.5 mm scaffold appearing to provide the best fit to the particular space in which it was implanted. Figure 27 is a photograph illustrating a 32 filament scaffold with a 17.5 mm diameter and 10 mm length after deployment in the ethmoid sinus after FESS.

[0194]

[0288] This study was conducted using 7.5 French and 9 French catheter systems. A 7.5F system was used to access all frontal sinuses, while a 9F system was used for device deployment into the ethmoid sinuses. Both catheter diameters were acceptable and the device functioned properly during use. A 90 degree bend was adequate to reach the frontal sinuses. Catheters of this type are described, for example, in "SINUS SCAFFOLD DELIVERY SYSTEMS," Attorney Docket No. 81354800002, Application No. 62 / 186,311, filed June 29, 2015, which is incorporated herein by reference.

[0195]

[0289] All devices are easily repositioned after deployment using standard tools. All devices were easily removed from the body. EXAMPLES

[0196]

[0290] Uniformly braided PLGA (10:90) or PLGA (75:25) Scaffolds (diameter = 8 mm, with 16 strands and braiding angle of 120°) were coated with a support coating made of poly(L-lactide-co-ε-caprolactone) (PLCL) cured with hexamethylene diisocyanate (HDI) in the presence of 1-dodecanol (DD) as a chain terminator and zinc octoate (Zn(Oct)2) as a catalyst. More specifically, 4-arm PLCL (40:60), HDI, DD, and Zn(Oct)2 were dissolved in dichloromethane (DCM) to make a stock solution for spray coating. The solution was spray coated onto the braided scaffolds using standard procedures. After drying overnight at room temperature under nitrogen environment, the scaffolds were fully cured at 60°C and then cut into 10 mm lengths for radial force and recovery testing. To improve the accumulation of elastomer nodes on the scaffolds, anisole (AN) was used as a co-solvent in the spray coating solution. After the drying and curing treatments described above, these scaffolds were also subjected to mechanical performance evaluation. Figures 28A-28D are optical microscope images of coated 8 mm scaffolds with 16 strands, with and without anisole as a co-solvent during spray coating, as follows: Figure 28A, PLGA (10:90) scaffold without anisole co-solvent; Figure 28B, PLGA (10:90) scaffold with anisole co-solvent; Figure 28C, PLGA (75:25) scaffold without anisole co-solvent; and Figure 28D, PLGA (75:25) with anisole co-solvent. Some properties of these scaffolds are summarized in Table 4.

[0197] [Table 4]

[0198]

[0291] All scaffolds showed good diameter recovery after simulated deployment. Depending on the node accumulation of the elastomer, the radial stiffness of the coated scaffolds is quite different. The base braid material does not significantly affect the radial stiffness of the coated scaffolds because these two materials have comparable elastic modulus. Similarly, 22 mm diameter PLGA (10:90) scaffolds were coated with the same elastomer in the absence and presence of anisole as a co-solvent during spray coating as described above. The scaffolds have 32 strands and braiding angles of 128 or 140. 29A-29C show optical images of scaffolds coated with and without anisole as a co-solvent during spray coating as follows: FIG. 29A, scaffold coated with 62 wt% elastomer by weight of base braid (i.e., ratio between mass of elastomer and mass of base braid) from a solution that does not contain anisole as a co-solvent; FIG. 29B, scaffold coated with 63 wt% elastomer by weight of base braid from a solution that contains anisole as a co-solvent; and FIG. 29C, scaffold coated with 100 wt% elastomer by weight of base braid from a solution that contains anisole as a co-solvent. As mentioned above, the presence of anisole in the scaffold coating improves the knot accumulation of elastomer obtained on the scaffold. Furthermore, more coating material may lead to further knot accumulation. To evaluate their mechanical performance, these 22 mm diameter scaffolds (length = 10 mm) were subjected to compression tests between two parallel flat aluminum plates assembled on an INSTRON apparatus. The scaffolds were compressed to 75% of their initial diameter and the forces at compression and rebound stages were recorded as a function of compression distance. Table 2 summarizes the compression force (Fc) and rebound force (Fr) at 50% compression. These forces are normalized to the length of the scaffold.

[0199] [Table 5]

[0200]

[0292] A higher lacing angle provides higher compression and rebound strength of the scaffold. Note that the accumulation of elastomer nodes, on the other hand, helps to strengthen the stiffness of the scaffold. However, by further increasing the amount of coating material, it was found that the compressive strength of the scaffold improved only slightly when a certain level of material was introduced onto the nodes. EXAMPLES

[0201]

[0293] In this example, the scaffold was prepared by mixing PLCL and mometasone furoate (M The MF-containing coating was further coated with an additional conformal coating containing a mixture of lactic acid and caprolactone (PLCL 70:30). The PLCL in the MF-containing coating contained approximately 70% (mol%) lactic acid, with the remainder being caprolactone (PLCL 70:30). A homogenous solution of MF and PLCL was prepared in ethyl formate and anisole (50:50 v / v). The solution was then spray-coated onto a d=10 mm scaffold with 16 strands or a d=22 mm scaffold with 32 strands. The amount of MF carried by each scaffold was controlled by the thickness and loading rate of the MF-containing coating. For the 10 mm scaffold, a drug layer containing 20 wt% MF (80 wt% PLCL) and 40 wt% MF (60 wt% PLCL), respectively, was coated onto the scaffold to obtain 240 μg and 590 μg per scaffold, respectively. In another case, 800 μg of MF was coated onto a 22 mm scaffold with 20 wt% MF (80 wt% PLCL) in the drug layer. The drug layers of these 22 mm and 10 mm scaffolds have comparable thicknesses.

[0202]

[0294] The in vitro release of MF from MF-coated scaffolds was determined. The scaffolds were incubated in a predefined amount of pH 7.4 PBS buffer containing 2% SDS at 37° C. with gentle shaking. At each indicated time point (see FIG. 30A and 30B), the buffer was completely removed, MF was quantified by HPLC, and fresh buffer was added. FIG. 30A and 30B show the cumulative absolute and mass percent MF released from these three sets of scaffolds, respectively. As expected, the amount of MF released daily depends on the total MF loading in the scaffolds. Meanwhile, 10 mm scaffolds with 40 wt% MF loading rate show a significantly slower release percentage than their analogs with 20 wt% MF loading rate. This result is different from what we observed for scaffolds with relatively low MF loading rate (e.g., 5 wt% to 20 wt%). We hypothesize that high loading rate of MF in the drug coating layer may lead to crystallization of MF, resulting in slower drug release. In this regard, tuning drug crystal size is the method of choice to control the drug release profile. Interestingly, 22 mm and 10 mm scaffolds with 20 wt % MF loading showed essentially identical percent release profiles, suggesting that the release profile is largely independent of scaffold dimensions when the drug layer has a similar thickness. EXAMPLES

[0203]

[0295] PLGA (10:90) scaffolds carrying 590 μg of MF and 530 μg of MF-loaded PLGA (75:25) scaffolds were fabricated with a diameter of 10 mm and a length of 6.5 m. These scaffolds were sterilized using ethylene oxide and implanted into the left and right maxillary sinus cavities of healthy young 4-6 month old New Zealand White rabbits. Scaffolds were explanted on days 3, 7, 14, and 28 and analyzed for residual drug content using HPLC-UV. Dynamic drug release (KDR) profiles were generated by subtracting the residual drug from the initially loaded drug determined gravimetrically. Tissue surrounding the scaffolds during deployment was collected and analyzed to obtain tissue drug concentrations. Figure 31 shows the in vivo KDR profiles for MF-coated PLGA (10:90) and PLGA (75:25) scaffolds. Figure 32 shows the MF concentrations in the sinus mucosa of sacrificed rabbits at given time points. FIG. 33 shows the total amount of MF on the scaffold combined with the amount of drug in the sinus mucosa of sacrificed rabbits at a given time point. EXAMPLES

[0204]

[0296] Braided PLGA 17.5 mm diameter scaffolds (PLGA 10:90, 32 strands) was synthesized using poly(L-lactide-co-ε-caprolactone), especially L-PL The scaffolds were then coated with a support coating made from MF (40:60) and cured with hexamethylene diisocyanate (HDI) in the presence of 1-dodecanol (DD) as a chain terminator with the optional use of Zn(Oct)2 catalyst as described above. An additional therapeutic agent-containing layer comprising 30 wt% MF and 70 wt% PLCL was then further coated onto the scaffold from a homogenous solution of MF and PLCL prepared in ethyl formate and anisole (70:30 v / v) as described above, with the exception that D,L-PLCL (80:20) or D,L-PLCL (90:10) was used as the carrier polymer instead of L-PLCL (70:30) as previously described in Example 10.

[0205]

[0297] The in vitro release of MF from these MF-coated scaffolds was measured as described in Example 1. The MF release rate was further determined as already described in 3.0. As shown in FIG. 34, the MF release rate associated with D,L-PLCL (80:20) (Tg=20° C.) is much faster than that of D,L-PLCL (90:10) (Tg=35° C.). Without wishing to be bound by theory, it is believed that the glass transition temperature (Tg) of the carrier polymer plays an important role in determining the drug release profile. In this regard, in the absence of Tg effects, it would normally be expected that the copolymers with the least amount of the more hydrophobic monomer (caprolactone), i.e., D,L-PLCL (90:10), would demonstrate faster release. EXAMPLES

[0206]

[0298] Braided PLGA 17.5 mm diameter scaffolds (PLGA 10:90, A 32-stranded PET film (100 mm x 100 mm) was coated with a support coating made of poly(L-lactide-co-ε-caprolactone), specifically L-PLCL (40:60), and cured with hexamethylene diisocyanate (HDI) in the presence of 1-dodecanol (DD) as a chain terminator with the optional use of the catalysts mentioned above. An additional therapeutic agent-containing layer comprising 30 wt% MF and 70 wt% polymeric material was then further coated onto the scaffold from a homogenous solution of MF and polymeric material prepared in ethyl formate and anisole (70:30 v / v) as described above, with the exception that in addition to L-PLCL (70:30) already mentioned in Example 10, the polymeric materials tested also included a blend of PLCL (70:30) and PLGA (75:25) in a 75:25 wt / wt ratio, a blend of PLCL (70:30) and PLGA (85:15) in a 75:25 wt / wt ratio, and a blend of PLCL (70:30) and PLA in a 75:25 wt / wt ratio.

[0207]

[0299] The in vitro release of MFs from these MF-coated scaffolds was demonstrated in Example 1. The MF release rate was further determined as previously described in 10. As shown in Figure 35, when a copolymer with a higher lactide content is blended with PLCL (70:30), the MF release rate decreases. Without wishing to be bound by theory, it is believed that the MF release rate decreases with increasing Tg of the polymer blended with PLCL (70:30). In this regard, PLA has the highest glass transition temperature of the three polymers used (PLGA (75:25) Tg about 50°C, PLGA (85:15) Tg about 55°C, and PLA Tg about 60°C). EXAMPLES

[0208]

[0300] Uniformly braided PLGA (10:90) scaffolds (diameter = 17.5 mm, length A 35 mm thick 10-mm thick 12-strand braid (having a braiding angle of 90° or 128°) was coated with a support coating made of poly(L-lactide-co-ε-caprolactone) (PLCL) cured with hexamethylene diisocyanate (HDI) in the presence of 1-dodecanol (DD) as a chain terminator with the optional use of the catalysts mentioned above, and further coated with a conformal coating comprising a mixture of PLCL and mometasone furoate as described in Example 10 above.

[0209]

[0301] To evaluate their mechanical performance, the plates were heated at 34 °C as shown in Fig. 38. These scaffolds 100 were placed sideways and compressed between the parallel plates 210a, 210b of a compression device 200 in a chamber maintained at 40° C. and 80% relative humidity. Stated differently, the scaffolds 100 were placed in compression between two parallel plates 210a, 210b such that the axis A of the tubular scaffold was parallel to the parallel plates and the tubular scaffold 100 was compressed between the parallel plates until the distance d between the parallel plates was a percentage of the initial unconstrained diameter, i.e., until the scaffold 100 was compressed in the compression device 200 such that the tubular scaffold had a first minimum width D equal to the distance d measured perpendicular to the axis A. The scaffolds were compressed to either 1.5 mm (8.6% of their initial diameter) or 3 mm (17.1% of their initial diameter). Each week, the scaffolds were removed from the compression apparatus and the recovered minimum width D (also referred to as the second minimum width D) of each scaffold was measured both immediately after removal from the compression apparatus and 6 hours after removal from the compression apparatus. The % recovery was calculated by dividing the second minimum width D immediately or 6 hours after removal from the compression plate by the first minimum width D (equal to the end-to-end distance d of the gap between the parallel plates), i.e., D (in mm) / 1.5 mm x 100 or D (in mm) / 3 mm x 100.

[0210]

[0302] In some embodiments, the scaffold is 10 cm wide at a distance d that is 8.5% of the as-manufactured diameter of the scaffold. After being maintained in compression for 10 weeks (e.g., a 17.5 mm scaffold is compressed to 1.5 mm) and after removal of the tubular scaffold 100 from compression for 6 hours, the first minimum width D (distance d) of the tubular scaffold may recover to a second minimum width D measured perpendicular to the axis that is at least 450% (e.g., 450% to 1000%) of the first minimum width D (1166% of theoretical maximum). In some embodiments, after being maintained in compression for 10 weeks (e.g., a 17.5 mm scaffold is compressed to 3.0 mm) and after removal of the tubular scaffold 100 from compression for 6 hours, the first minimum width D of the tubular scaffold may recover to a second minimum width D measured perpendicular to the axis that is at least 250% (e.g., 250% to 500%) of the first minimum width D (583% of theoretical maximum) of the first minimum width D.

[0211]

[0303] Extraction of scaffolds with 90° and 128° braided angles compressed to 1.5 mm The results immediately after removal are shown in FIG. 36A and the results immediately after removal of the 90° and 128° braid angle scaffolds compressed to 3.0 mm are shown in FIG. 36B. As can be seen from FIG. 36A, the immediate recovery rate of the 90° braid angle scaffold from 1.5 mm compression was about 230% after 1 week and about 250% after 10 weeks. The immediate recovery rate of the 128° braid angle scaffold from 1.5 mm compression was about 175% after 1 week and about 190% after 10 weeks. As can be seen from FIG. 36B, the immediate recovery rate of the 90° braid angle scaffold from 3.0 mm compression was about 165% after 1 week and about 170% after 10 weeks. The immediate recovery rate of the 128° braid angle scaffold from 3.0 mm compression was about 140% after 1 week and about 175% after 10 weeks.

[0212]

[0304] Extraction of scaffolds with 90° and 128° braided angles compressed to 1.5 mm Results after 6 hours of removal are presented in FIG. 37A and Table 6, and results after 6 hours of removal of 90° and 128° braided angle scaffolds compressed to 3.0 mm are presented in FIG. 37B and Table 7. The 90° braided angle scaffolds recovered about 540% after 1 week and about 510% after 10 weeks of 1.5 mm compression for 6 hours. The 128° braided angle scaffolds recovered about 550% after 1 week and about 480% after 10 weeks of 1.0 mm compression for 6 hours. The 90° braided angle scaffolds recovered about 280% after 1 week and about 270% after 10 weeks of 3.0 mm compression for 6 hours. The recovery rate of the 128° braid angle scaffolds after 6 hours from a 3.0 mm compression was approximately 300% after 1 week and approximately 190% after 10 weeks.

[0213] [Table 6]

[0214] [Table 7]

[0215]

[0305] As can be seen in Figure 37A, the compression of the scaffold with a braiding angle of 90° at 1.5 mm The percent recovery from 1.5 mm compression for the 128° braided angle scaffolds at all time points appeared similar to the percent recovery from 1.5 mm compression for the 128° braided angle scaffolds, each showing a significant drop in percent recovery between weeks 1 and 2. Representative percent recovery data are presented in Table 6.

[0216]

[0306] Similarly, as can be seen from FIG. 37B, the 3.0 m The percent recovery from 3.0 mm compression appears similar to the percent recovery from 3.0 mm compression to 7 weeks for the 128° braid angle scaffolds, each showing a significant drop in percent recovery between weeks 1 and 2. Representative percent recovery data is presented in Table 7.

[0217]

[0307] Although various embodiments have been particularly illustrated and described herein, modifications of the present disclosure may be made without departing from the spirit and scope of the present invention. It will be appreciated that modifications and variations are encompassed by the above teachings and within the scope of the appended claims without departing from the spirit and intended scope of the present disclosure. For example, although the scaffolds are described herein with respect to sinus applications, such scaffolds may be useful in other applications, such as stenting the Eustachian tube.

Claims

1. 1. A delivery system comprising: (a) a self-expanding, drug-eluting scaffold comprised of filaments, the filaments comprising an elastomeric coating and a drug layer comprising a steroidal anti-inflammatory drug; and (b) a delivery catheter, the scaffold being positioned within the delivery catheter in a constrained configuration, the elastomeric coating exerting a sustained outward force on the scaffold that acts to tend to expand to conform to the shape of the middle meatus space when the scaffold is released from the constrained configuration.

2. 10. The delivery system of claim 1, wherein the scaffold has an unconstrained diameter of 5 mm to 60 mm.

3. 10. The delivery system of claim 1, wherein the scaffold has an unconstrained diameter of 8 mm.

4. 10. The delivery system of claim 1, wherein the scaffold has an unconstrained diameter of 10 mm.

5. 10. The delivery system of claim 1, wherein the scaffold has an unconstrained diameter of 20 mm.

6. 10. The delivery system of claim 1, wherein the scaffold has an unconstrained diameter of 30 mm.

7. The delivery system of claim 1 , wherein the elastomeric coating comprises an elastomer selected from the group consisting of thermoset elastomers and thermoplastic elastomers.

8. 10. The delivery system of claim 1, wherein the scaffold is designed to release drug over a period of 8 to 26 weeks.

Images